����JFIFXX�����    $.' ",#(7),01444'9=82<.342  2!!22222222222222222222222222222222222222222222222222����"��4�� ���,�PG"Z_�4�˷����kjز�Z�,F+��_z�,�© �����zh6�٨�ic�fu���#ډb���_�N�?��wQ���5-�~�I���8����TK<5o�Iv-�����k�_U_�����~b�M��d����Ӝ�U�Hh��?]��E�w��Q���k�{��_}qFW7HTՑ��Y��F�?_�'ϔ��_�Ջt��=||I ��6�έ"�����D���/[�k�9���Y�8ds|\���Ҿp6�Ҵ���]��.����6�z<�v��@]�i%��$j��~�g��J>��no����pM[me�i$[����s�o�ᘨ�˸ nɜG-�ĨU�ycP�3.DB�li�;��hj���x7Z^�N�h������N3u{�:j�x�힞��#M&��jL P@_���� P��&��o8������9�����@Sz6�t7#O�ߋ �s}Yf�T���lmr����Z)'N��k�۞p����w\�Tȯ?�8`�O��i{wﭹW�[�r�� ��Q4F�׊���3m&L�=��h3����z~��#�\�l :�F,j@�� ʱ�wQT����8�"kJO���6�֚l����}���R�>ډK���]��y����&����p�}b��;N�1�m�r$�|��7�>e�@B�TM*-iH��g�D�)� E�m�|�ؘbҗ�a��Ҿ����t4���o���G��*oCN�rP���Q��@z,|?W[0�����:�n,jWiE��W��$~/�hp\��?��{(�0���+�Y8rΟ�+����>S-S����VN;�}�s?.����� w�9��˟<���Mq4�Wv'��{)0�1mB��V����W[�����8�/<� �%���wT^�5���b��)iM� pg�N�&ݝ��VO~�q���u���9� ����!��J27����$O-���! �:�%H��� ـ����y�ΠM=t{!S�� oK8������t<����è:a������[�����ա�H���~��w��Qz`�po�^ ����Q��n� �,uu�C�$ ^���,������8�#��:�6��e�|~���!�3�3.�\0��q��o�4`.|� ����y�Q�`~;�d�ׯ,��O�Zw�������`73�v�܋�<���Ȏ�� ـ4k��5�K�a�u�=9Yd��$>x�A�&�� j0� ���vF��� Y�|�y��� ~�6�@c��1vOp�Ig����4��l�OD���L����� R���c���j�_�uX6��3?nk��Wy�f;^*B� ��@�~a�`��Eu������+���6�L��.ü>��}y���}_�O�6�͐�:�YrG�X��kG�����l^w���~㒶sy��Iu�!� W ��X��N�7BV��O��!X�2����wvG�R�f�T#�����t�/?���%8�^�W�aT��G�cL�M���I��(J����1~�8�?aT ���]����AS�E��(��*E}� 2��#I/�׍qz��^t�̔���b�Yz4x���t�){ OH��+(E��A&�N�������XT��o��"�XC��'���)}�J�z�p� ��~5�}�^����+�6����w��c��Q�|Lp�d�H��}�(�.|����k��c4^�"�����Z?ȕ ��a<�L�!039C� �Eu�C�F�Ew�ç ;�n?�*o���B�8�bʝ���'#Rqf���M}7����]����s2tcS{�\icTx;�\��7K���P���ʇ Z O-��~��c>"��?�������P��E��O�8��@�8��G��Q�g�a�Վ���󁶠�䧘��_%#r�>�1�z�a��eb��qcPѵ��n���#L��� =��׀t� L�7�`��V���A{�C:�g���e@�w1 Xp3�c3�ġ����p��M"'-�@n4���fG��B3�DJ�8[Jo�ߐ���gK)ƛ��$���� ���8�3�����+���� �����6�ʻ���� ���S�kI�*KZlT _`���?��K����QK�d����B`�s}�>���`��*�>��,*@J�d�oF*����弝��O}�k��s��]��y�ߘ��c1G�V���<=�7��7����6�q�PT��tXԀ�!9*4�4Tހ3XΛex�46���Y��D ����� �BdemDa����\�_l,��G�/���֌7���Y�](�xTt^%�GE�����4�}bT���ڹ�����;Y)���B�Q��u��>J/J �⮶.�XԄ��j�ݳ�+E��d ��r�5�_D�1 ��o�� �B�x�΢�#���<��W�����8���R6�@g�M�.��� dr�D��>(otU��@x=��~v���2� ӣ�d�oBd��3�eO�6�㣷�����ݜ6��6Y��Qz`��S��{���\P�~z m5{J/L��1������<�e�ͅPu�b�]�ϔ���'������f�b� Zpw��c`"��i���BD@:)ִ�:�]��hv�E�w���T�l��P���"Ju�}��وV J��G6��. J/�Qgl߭�e�����@�z�Zev2u�)]կ�����7x���s�M�-<ɯ�c��r�v�����@��$�ޮ}lk���a���'����>x��O\�ZFu>�����ck#��&:��`�$�ai�>2Δ����l���oF[h��lE�ܺ�Πk:)���`�� $[6�����9�����kOw�\|���8}������ބ:��񶐕��I�A1/�=�2[�,�!��.}gN#�u����b��� ~��݊��}34q����d�E��Lc��$��"�[q�U�硬g^��%B �z���r�pJ�ru%v\h1Y�ne`ǥ:g���pQM~�^�Xi� ��`S�:V29.�P���V�?B�k�� AEvw%�_�9C�Q����wKekPؠ�\�;Io d�{ ߞo�c1eP����\� `����E=���@K<�Y���eڼ�J���w����{av�F�'�M�@/J��+9p���|]�����Iw &`��8���&M�hg��[�{��Xj��%��Ӓ�$��(����ʹN���<>�I���RY���K2�NPlL�ɀ)��&e����B+ь����( � �JTx���_?EZ� }@ 6�U���뙢ط�z��dWI�n` D����噥�[��uV��"�G&Ú����2g�}&m��?ċ�"����Om#��������� ��{�ON��"S�X��Ne��ysQ���@Fn��Vg���dX�~nj�]J�<�K]:��FW��b�������62�=��5f����JKw��bf�X�55��~J �%^����:�-�QIE��P��v�nZum� z � ~ə ���� ���ة����;�f��\v���g�8�1��f24;�V���ǔ�)����9���1\��c��v�/'Ƞ�w�������$�4�R-��t���� e�6�/�ġ �̕Ecy�J���u�B���<�W�ַ~�w[B1L۲�-JS΂�{���΃������A��20�c#��@ 0!1@AP"#2Q`$3V�%45a6�FRUq��� ����^7ׅ,$n�������+��F�`��2X'��0vM��p�L=������5��8������u�p~���.�`r�����\���O��,ư�0oS ��_�M�����l���4�kv\JSd���x���SW�<��Ae�IX����������$I���w�:S���y���›R��9�Q[���,�5�;�@]�%���u�@ *ro�lbI �� ��+���%m:�͇ZV�����u�̉����θau<�fc�.����{�4Ա� �Q����*�Sm��8\ujqs]{kN���)qO�y�_*dJ�b�7���yQqI&9�ԌK!�M}�R�;������S�T���1���i[U�ɵz�]��U)V�S6���3$K{�ߊ<�(� E]Զ[ǼENg�����'�\?#)Dkf��J���o��v���'�%ƞ�&K�u�!��b�35LX�Ϸ��63$K�a�;�9>,R��W��3�3� d�JeTYE.Mϧ��-�o�j3+y��y^�c�������VO�9NV\nd�1 ��!͕_)a�v;����թ�M�lWR1��)El��P;��yوÏ�u 3�k�5Pr6<�⒲l�!˞*��u־�n�!�l:����UNW ��%��Chx8vL'��X�@��*��)���̮��ˍ��� ���D-M�+J�U�kvK����+�x8��cY������?�Ԡ��~3mo��|�u@[XeY�C�\Kp�x8�oC�C�&����N�~3-H���� ��MX�s�u<`���~"WL��$8ξ��3���a�)|:@�m�\���^�`�@ҷ)�5p+��6���p�%i)P M���ngc�����#0Aruz���RL+xSS?���ʮ}()#�t��mˇ!��0}}y����<�e� �-ή�Ԩ��X������ MF���ԙ~l L.3���}�V뽺�v�����멬��Nl�)�2����^�Iq��a��M��qG��T�����c3#������3U�Ǎ���}��לS�|qa��ڃ�+���-��2�f����/��bz��ڐ�� �ݼ[2�ç����k�X�2�* �Z�d���J�G����M*9W���s{��w���T��x��y,�in�O�v��]���n����P�$�JB@=4�OTI�n��e�22a\����q�d���%�$��(���:���: /*�K[PR�fr\nڙdN���F�n�$�4�[�� U�zƶ����� �mʋ���,�ao�u 3�z� �x��Kn����\[��VFmbE;�_U��&V�Gg�]L�۪&#n%�$ɯ�dG���D�TI=�%+AB�Ru#��b4�1�»x�cs�YzڙJG��f��Il��d�eF'T� iA��T���uC�$����Y��H?����[!G`}���ͪ� �纤Hv\������j�Ex�K���!���OiƸ�Yj�+u-<���'q����uN�*�r\��+�]���<�wOZ.fp�ێ��,-*)V?j-kÊ#�`�r��dV����(�ݽBk�����G�ƛk�QmUڗe��Z���f}|����8�8��a���i��3'J�����~G_�^���d�8w������ R�`(�~�.��u���l�s+g�bv���W���lGc}��u���afE~1�Ue������Z�0�8�=e�� f@/�jqEKQQ�J��oN��J���W5~M>$6�Lt�;$ʳ{���^��6�{����v6���ķܰg�V�cnn �~z�x�«�,2�u�?cE+Ș�H؎�%�Za�)���X>uW�Tz�Nyo����s���FQƤ��$��*�&�LLXL)�1�" L��eO��ɟ�9=���:t��Z���c��Ž���Y?�ӭV�wv�~,Y��r�ۗ�|�y��GaF�����C�����.�+� ���v1���fήJ�����]�S��T��B��n5sW}y�$��~z�'�c ��8 ��� ,! �p��VN�S��N�N�q��y8z˱�A��4��*��'������2n<�s���^ǧ˭P�Jޮɏ�U�G�L�J�*#��<�V��t7�8����TĜ>��i}K%,���)[��z�21z ?�N�i�n1?T�I�R#��m-�����������������1����lA�`��fT5+��ܐ�c�q՝��ʐ��,���3�f2U�եmab��#ŠdQ�y>\��)�SLY����w#��.���ʑ�f��� ,"+�w�~�N�'�c�O�3F�������N<���)j��&��,-� �љ���֊�_�zS���TǦ����w�>��?�������n��U仆�V���e�����0���$�C�d���rP �m�׈e�Xm�Vu� �L��.�bֹ��� �[Դaզ���*��\y�8�Է:�Ez\�0�Kq�C b��̘��cө���Q��=0Y��s�N��S.���3.���O�o:���#���v7�[#߫ ��5�܎�L���Er4���9n��COWlG�^��0k�%<���ZB���aB_���������'=��{i�v�l�$�uC���mƎҝ{�c㱼�y]���W�i ��ߧc��m�H� m�"�"�����;Y�ߝ�Z�Ǔ�����:S#��|}�y�,/k�Ld� TA�(�AI$+I3��;Y*���Z��}|��ӧO��d�v��..#:n��f>�>���ȶI�TX��� 8��y����"d�R�|�)0���=���n4��6ⲑ�+��r<�O�܂~zh�z����7ܓ�HH�Ga롏���nCo�>������a ���~]���R���̲c?�6(�q�;5%� |�uj�~z8R=X��I�V=�|{v�Gj\gc��q����z�؋%M�ߍ����1y��#��@f^���^�>N�����#x#۹��6�Y~�?�dfPO��{��P�4��V��u1E1J �*|���%���JN��`eWu�zk M6���q t[�� ��g�G���v��WIG��u_ft����5�j�"�Y�:T��ɐ���*�;� e5���4����q$C��2d�}���� _S�L#m�Yp��O�.�C�;��c����Hi#֩%+) �Ӎ��ƲV���SYź��g |���tj��3�8���r|���V��1#;.SQ�A[���S������#���`n�+���$��$I �P\[�@�s��(�ED�z���P��])8�G#��0B��[ى��X�II�q<��9�~[Z멜�Z�⊔IWU&A>�P~�#��dp<�?����7���c��'~���5 ��+$���lx@�M�dm��n<=e�dyX��?{�|Aef ,|n3�<~z�ƃ�uۧ�����P��Y,�ӥQ�*g�#먙R�\���;T��i,��[9Qi歉����c>]9�� ��"�c��P�� �Md?٥��If�ت�u��k��/����F��9�c*9��Ǎ:�ØF���z�n*�@|I�ށ9����N3{'��[�'ͬ�Ҳ4��#}��!�V� Fu��,�,mTIk���v C�7v���B�6k�T9��1�*l� '~��ƞF��lU��'�M ����][ΩũJ_�{�i�I�n��$���L�� j��O�dx�����kza۪��#�E��Cl����x˘�o�����V���ɞ�ljr��)�/,�߬h�L��#��^��L�ф�,íMƁe�̩�NB�L�����iL����q�}��(��q��6IçJ$�W�E$��:������=#����(�K�B����zђ <��K(�N�۫K�w��^O{!����)�H���>x�������lx�?>Պ�+�>�W���,Ly!_�D���Ō�l���Q�!�[ �S����J��1��Ɛ�Y}��b,+�Lo�x�ɓ)����=�y�oh�@�꥟/��I��ѭ=��P�y9��� �ۍYӘ�e+�p�Jnϱ?V\SO%�(�t� ���=?MR�[Ș�����d�/ ��n�l��B�7j� ��!�;ӥ�/�[-���A�>�dN�sLj ��,ɪv��=1c�.SQ�O3�U���ƀ�ܽ�E����������̻��9G�ϷD�7(�}��Ävӌ\�y�_0[w ���<΍>����a_��[0+�L��F.�޺��f�>oN�T����q;���y\��bՃ��y�jH�<|q-eɏ�_?_9+P���Hp$�����[ux�K w�Mw��N�ی'$Y2�=��q���KB��P��~������Yul:�[<����F1�2�O���5=d����]Y�sw:���Ϯ���E��j,_Q��X��z`H1,#II ��d�wr��P˂@�ZJV����y$�\y�{}��^~���[:N����ߌ�U�������O��d�����ؾe��${p>G��3c���Ė�lʌ�� ת��[��`ϱ�-W����dg�I��ig2��� ��}s ��ؤ(%#sS@���~���3�X�nRG�~\jc3�v��ӍL��M[JB�T��s3}��j�Nʖ��W����;7��ç?=X�F=-�=����q�ߚ���#���='�c��7���ڑW�I(O+=:uxq�������������e2�zi+�kuG�R��������0�&e�n���iT^J����~\jy���p'dtG��s����O��3����9* �b#Ɋ�� p������[Bws�T�>d4�ۧs���nv�n���U���_�~,�v����ƜJ1��s�� �QIz��)�(lv8M���U=�;����56��G���s#�K���MP�=��LvyGd��}�VwWBF�'�à �?MH�U�g2�� ����!�p�7Q��j��ڴ����=��j�u��� Jn�A s���uM������e��Ɔ�Ҕ�!)'��8Ϣ�ٔ��ޝ(��Vp���צ֖d=�IC�J�Ǡ{q������kԭ�߸���i��@K����u�|�p=..�*+����x�����z[Aqġ#s2a�Ɗ���RR�)*HRsi�~�a &f��M��P����-K�L@��Z��Xy�'x�{}��Zm+���:�)�) IJ�-i�u���� ���ܒH��'�L(7�y�GӜq���� j��� 6ߌg1�g�o���,kر���tY�?W,���p���e���f�OQS��!K�۟cҒA�|ս�j�>��=⬒��˧L[�� �߿2JaB~R��u�:��Q�] �0H~���]�7��Ƽ�I���(}��cq '�ήET���q�?f�ab���ӥvr� �)o��-Q��_'����ᴎo��K������;��V���o��%���~OK ����*��b�f:���-ťIR��`B�5!RB@���ï�� �u �̯e\�_U�_������� g�ES��3�������QT��a����x����U<~�c?�*�#]�MW,[8O�a�x��]�1bC|踤�P��lw5V%�)�{t�<��d��5���0i�XSU��m:��Z�┵�i�"��1�^B�-��P�hJ��&)O��*�D��c�W��vM��)����}���P��ܗ-q����\mmζZ-l@�}��a��E�6��F�@��&Sg@���ݚ�M����� ȹ 4����#p�\H����dYDo�H���"��\��..R�B�H�z_�/5˘����6��KhJR��P�mƶi�m���3�,#c�co��q�a)*Pt����R�m�k�7x�D�E�\Y�閣_X�<���~�)���c[[�BP����6�Yq���S��0����%_����;��Àv�~�| VS؇ ��'O0��F0��\���U�-�d@�����7�SJ*z��3n��y��P����O���������m�~�P�3|Y��ʉr#�C�<�G~�.,! ���bqx���h~0=��!ǫ�jy����l�O,�[B��~��|9��ٱ����Xly�#�i�B��g%�S��������tˋ���e���ې��\[d�t)��.+u�|1 ������#�~Oj����hS�%��i.�~X���I�H�m��0n���c�1uE�q��cF�RF�o���7� �O�ꮧ� ���ۛ{��ʛi5�rw?׌#Qn�TW��~?y$��m\�\o����%W� ?=>S�N@�� �Ʈ���R����N�)�r"C�:��:����� �����#��qb��Y�. �6[��2K����2u�Ǧ�HYR��Q�MV��� �G�$��Q+.>�����nNH��q�^��� ����q��mM��V��D�+�-�#*�U�̒ ���p욳��u:�������IB���m���PV@O���r[b= �� ��1U�E��_Nm�yKbN�O���U�}�the�`�|6֮P>�\2�P�V���I�D�i�P�O;�9�r�mAHG�W�S]��J*�_�G��+kP�2����Ka�Z���H�'K�x�W�MZ%�O�YD�Rc+o��?�q��Ghm��d�S�oh�\�D�|:W������UA�Qc yT�q������~^�H��/��#p�CZ���T�I�1�ӏT����4��"�ČZ�����}��`w�#�*,ʹ�� ��0�i��課�Om�*�da��^gJ݅{���l�e9uF#T�ֲ��̲�ٞC"�q���ߍ ոޑ�o#�XZTp����@ o�8��(jd��xw�]�,f���`~�|,s��^����f�1���t��|��m�򸄭/ctr��5s��7�9Q�4�H1꠲BB@l9@���C�����+�wp�xu�£Yc�9��?`@#�o�mH�s2��)�=��2�.�l����jg�9$�Y�S�%*L������R�Y������7Z���,*=�䷘$�������arm�o�ϰ���UW.|�r�uf����IGw�t����Zwo��~5 ��YյhO+=8fF�)�W�7�L9lM�̘·Y���֘YLf�큹�pRF���99.A �"wz��=E\Z���'a� 2��Ǚ�#;�'}�G���*��l��^"q��+2FQ� hj��kŦ��${���ޮ-�T�٭cf�|�3#~�RJ����t��$b�(R��(����r���dx� >U b�&9,>���%E\� Ά�e�$��'�q't��*�א���ެ�b��-|d���SB�O�O��$�R+�H�)�܎�K��1m`;�J�2�Y~9��O�g8=vqD`K[�F)k�[���1m޼c��n���]s�k�z$@��)!I �x՝"v��9=�ZA=`Ɠi �:�E��)`7��vI��}d�YI�_ �o�:ob���o ���3Q��&D&�2=�� �Ά��;>�h����y.*ⅥS������Ӭ�+q&����j|UƧ����}���J0��WW< ۋS�)jQR�j���Ư��rN)�Gű�4Ѷ(�S)Ǣ�8��i��W52���No˓� ۍ%�5brOn�L�;�n��\G����=�^U�dI���8$�&���h��'���+�(������cȁ߫k�l��S^���cƗjԌE�ꭔ��gF���Ȓ��@���}O���*;e�v�WV���YJ\�]X'5��ղ�k�F��b 6R�o՜m��i N�i����>J����?��lPm�U��}>_Z&�KK��q�r��I�D�Չ~�q�3fL�:S�e>���E���-G���{L�6p�e,8��������QI��h��a�Xa��U�A'���ʂ���s�+טIjP�-��y�8ۈZ?J$��W�P� ��R�s�]��|�l(�ԓ��sƊi��o(��S0��Y� 8�T97.�����WiL��c�~�dxc�E|�2!�X�K�Ƙਫ਼�$((�6�~|d9u+�qd�^3�89��Y�6L�.I�����?���iI�q���9�)O/뚅����O���X��X�V��ZF[�یgQ�L��K1���RҖr@v�#��X�l��F���Нy�S�8�7�kF!A��sM���^rkp�jP�DyS$N���q��nxҍ!U�f�!eh�i�2�m���`�Y�I�9r�6� �TF���C}/�y�^���Η���5d�'��9A-��J��>{�_l+�`��A���[�'��յ�ϛ#w:݅�%��X�}�&�PSt�Q�"�-��\縵�/����$Ɨh�Xb�*�y��BS����;W�ջ_mc�����vt?2}1�;qS�d�d~u:2k5�2�R�~�z+|HE!)�Ǟl��7`��0�<�,�2*���Hl-��x�^����'_TV�gZA�'j� ^�2Ϊ��N7t�����?w�� �x1��f��Iz�C-Ȗ��K�^q�;���-W�DvT�7��8�Z�������� hK�(P:��Q- �8�n�Z���܃e貾�<�1�YT<�,�����"�6{/ �?�͟��|1�:�#g��W�>$����d��J��d�B��=��jf[��%rE^��il:��B���x���Sּ�1հ��,�=��*�7 fcG��#q� �eh?��2�7�����,�!7x��6�n�LC�4x��},Geǝ�tC.��vS �F�43��zz\��;QYC,6����~;RYS/6���|2���5���v��T��i����������mlv��������&� �nRh^ejR�LG�f���? �ۉҬܦƩ��|��Ȱ����>3����!v��i�ʯ�>�v��オ�X3e���_1z�Kȗ\<������!�8���V��]��?b�k41�Re��T�q��mz��TiOʦ�Z��Xq���L������q"+���2ۨ��8}�&N7XU7Ap�d�X��~�׿��&4e�o�F��� �H����O���č�c�� 懴�6���͉��+)��v;j��ݷ�� �UV�� i��� j���Y9GdÒJ1��詞�����V?h��l����l�cGs�ځ�������y�Ac�����\V3�? �� ܙg�>qH�S,�E�W�[�㺨�uch�⍸�O�}���a��>�q�6�n6����N6�q������N ! 1AQaq�0@����"2BRb�#Pr���3C`��Scst���$4D���%Td�� ?���N����a��3��m���C���w��������xA�m�q�m���m������$����4n淿t'��C"w��zU=D�\R+w�p+Y�T�&�պ@��ƃ��3ޯ?�Aﶂ��aŘ���@-�����Q�=���9D��ռ�ѻ@��M�V��P��܅�G5�f�Y<�u=,EC)�<�Fy'�"�&�չ�X~f��l�KԆV��?�� �W�N����=(� �;���{�r����ٌ�Y���h{�١������jW����P���Tc�����X�K�r��}���w�R��%��?���E��m�� �Y�q|����\lEE4���r���}�lsI�Y������f�$�=�d�yO����p�����yBj8jU�o�/�S��?�U��*������ˍ�0������u�q�m [�?f����a�� )Q�>����6#������� ?����0UQ����,IX���(6ڵ[�DI�MNލ�c&���υ�j\��X�R|,4��� j������T�hA�e��^���d���b<����n�� �즇�=!���3�^�`j�h�ȓr��jẕ�c�,ٞX����-����a�ﶔ���#�$��]w�O��Ӫ�1y%��L�Y<�wg#�ǝ�̗`�x�xa�t�w��»1���o7o5��>�m뭛C���Uƃߜ}�C���y1Xνm�F8�jI���]����H���ۺиE@I�i;r�8ӭ����V�F�Շ| ��&?�3|x�B�MuS�Ge�=Ӕ�#BE5G�����Y!z��_e��q�р/W>|-�Ci߇�t�1ޯќd�R3�u��g�=0 5��[?�#͏��q�cf���H��{ ?u�=?�?ǯ���}Z��z���hmΔ�BFTW�����<�q�(v� ��!��z���iW]*�J�V�z��gX֧A�q�&��/w���u�gYӘa���; �i=����g:��?2�dž6�ى�k�4�>�Pxs����}������G�9��3 ���)gG�R<>r h�$��'nc�h�P��Bj��J�ҧH� -��N1���N��?��~��}-q!=��_2hc�M��l�vY%UE�@|�v����M2�.Y[|y�"Eï��K�ZF,�ɯ?,q�?v�M 80jx�"�;�9vk�����+ ֧�� �ȺU��?�%�vcV��mA�6��Qg^M����A}�3�nl� QRN�l8�kkn�'�����(��M�7m9و�q���%ޟ���*h$Zk"��$�9��: �?U8�Sl��,,|ɒ��xH(ѷ����Gn�/Q�4�P��G�%��Ա8�N��!� �&�7�;���eKM7�4��9R/%����l�c>�x;������>��C�:�����t��h?aKX�bhe�ᜋ^�$�Iհ �hr7%F$�E��Fd���t��5���+�(M6�t����Ü�UU|zW�=a�Ts�Tg������dqP�Q����b'�m���1{|Y����X�N��b �P~��F^F:����k6�"�j!�� �I�r�`��1&�-$�Bevk:y���#yw��I0��x��=D�4��tU���P�ZH��ڠ底taP��6����b>�xa����Q�#� WeF��ŮNj�p�J* mQ�N����*I�-*�ȩ�F�g�3 �5��V�ʊ�ɮ�a��5F���O@{���NX��?����H�]3��1�Ri_u��������ѕ�� ����0��� F��~��:60�p�͈�S��qX#a�5>���`�o&+�<2�D����: �������ڝ�$�nP���*)�N�|y�Ej�F�5ټ�e���ihy�Z �>���k�bH�a�v��h�-#���!�Po=@k̆IEN��@��}Ll?j�O������߭�ʞ���Q|A07x���wt!xf���I2?Z��<ץ�T���cU�j��]��陎Ltl �}5�ϓ��$�,��O�mˊ�;�@O��jE��j(�ا,��LX���LO���Ц�90�O �.����a��nA���7������j4 ��W��_ٓ���zW�jcB������y՗+EM�)d���N�g6�y1_x��p�$Lv:��9�"z��p���ʙ$��^��JԼ*�ϭ����o���=x�Lj�6�J��u82�A�H�3$�ٕ@�=Vv�]�'�qEz�;I˼��)��=��ɯ���x �/�W(V���p�����$ �m�������u�����񶤑Oqˎ�T����r��㠚x�sr�GC��byp�G��1ߠ�w e�8�$⿄����/�M{*}��W�]˷.�CK\�ުx���/$�WPw���r� |i���&�}�{�X� �>��$-��l���?-z���g����lΆ���(F���h�vS*���b���߲ڡn,|)mrH[���a�3�ר�[1��3o_�U�3�TC�$��(�=�)0�kgP���� ��u�^=��4 �WYCҸ:��vQ�ר�X�à��tk�m,�t*��^�,�}D*� �"(�I��9R����>`�`��[~Q]�#af��i6l��8���6�:,s�s�N6�j"�A4���IuQ��6E,�GnH��zS�HO�uk�5$�I�4��ؤ�Q9�@��C����wp�BGv[]�u�Ov���0I4���\��y�����Q�Ѹ��~>Z��8�T��a��q�ޣ;z��a���/��S��I:�ܫ_�|������>=Z����8:�S��U�I�J��"IY���8%b8���H��:�QO�6�;7�I�S��J��ҌAά3��>c���E+&jf$eC+�z�;��V����� �r���ʺ������my�e���aQ�f&��6�ND��.:��NT�vm�<- u���ǝ\MvZY�N�NT��-A�>jr!S��n�O 1�3�Ns�%�3D@���`������ܟ 1�^c<���� �a�ɽ�̲�Xë#�w�|y�cW�=�9I*H8�p�^(4���՗�k��arOcW�tO�\�ƍR��8����'�K���I�Q�����?5�>[�}��yU�ײ -h��=��% q�ThG�2�)���"ו3]�!kB��*p�FDl�A���,�eEi�H�f�Ps�����5�H:�Փ~�H�0Dت�D�I����h�F3�������c��2���E��9�H��5�zԑ�ʚ�i�X�=:m�xg�hd(�v����׊�9iS��O��d@0ڽ���:�p�5�h-��t�&���X�q�ӕ,��ie�|���7A�2���O%P��E��htj��Y1��w�Ѓ!����  ���� ࢽ��My�7�\�a�@�ţ�J �4�Ȼ�F�@o�̒?4�wx��)��]�P��~�����u�����5�����7X ��9��^ܩ�U;Iꭆ 5 �������eK2�7(�{|��Y׎ �V��\"���Z�1� Z�����}��(�Ǝ"�1S���_�vE30>���p;� ΝD��%x�W�?W?v����o�^V�i�d��r[��/&>�~`�9Wh��y�;���R��� ;;ɮT��?����r$�g1�K����A��C��c��K��l:�'��3 c�ﳯ*"t8�~l��)���m��+U,z��`(�>yJ�?����h>��]��v��ЍG*�{`��;y]��I�T� ;c��NU�fo¾h���/$���|NS���1�S�"�H��V���T���4��uhǜ�]�v;���5�͠x��'C\�SBpl���h}�N����� A�Bx���%��ޭ�l��/����T��w�ʽ]D�=����K���ž�r㻠l4�S�O?=�k �M:� ��c�C�a�#ha���)�ѐxc�s���gP�iG��{+���x���Q���I= �� z��ԫ+ �8"�k�ñ�j=|����c ��y��CF��/��*9ж�h{ �?4�o� ��k�m�Q�N�x��;�Y��4膚�a�w?�6�>e]�����Q�r�:����g�,i"�����ԩA�*M�<�G��b�if��l^M��5� �Ҩ�{����6J��ZJ�����P�*�����Y���ݛu�_4�9�I8�7���������,^ToR���m4�H��?�N�S�ѕw��/S��甍�@�9H�S�T��t�ƻ���ʒU��*{Xs�@����f�����֒Li�K{H�w^���������Ϥm�tq���s� ���ք��f:��o~s��g�r��ט� �S�ѱC�e]�x���a��) ���(b-$(�j>�7q�B?ӕ�F��hV25r[7 Y� }L�R��}����*sg+��x�r�2�U=�*'WS��ZDW]�WǞ�<��叓���{�$�9Ou4��y�90-�1�'*D`�c�^o?(�9��u���ݐ��'PI&� f�Jݮ�������:wS����jfP1F:X �H�9dԯ���˝[�_54 �}*;@�ܨ�� ð�yn�T���?�ןd�#���4rG�ͨ��H�1�|-#���Mr�S3��G�3�����)�.᧏3v�z֑��r����$G"�`j �1t��x0<Ɔ�Wh6�y�6��,œ�Ga��gA����y��b��)��h�D��ß�_�m��ü �gG;��e�v��ݝ�nQ� ��C����-�*��o���y�a��M��I�>�<���]obD��"�:���G�A��-\%LT�8���c�)��+y76���o�Q�#*{�(F�⽕�y����=���rW�\p���۩�c���A���^e6��K������ʐ�cVf5$�'->���ՉN"���F�"�UQ@�f��Gb~��#�&�M=��8�ט�JNu9��D��[̤�s�o�~������ G��9T�tW^g5y$b��Y'��س�Ǵ�=��U-2 #�MC�t(�i� �lj�@Q 5�̣i�*�O����s�x�K�f��}\��M{E�V�{�υ��Ƈ�����);�H����I��fe�Lȣr�2��>��W�I�Ȃ6������i��k�� �5�YOxȺ����>��Y�f5'��|��H+��98pj�n�.O�y�������jY��~��i�w'������l�;�s�2��Y��:'lg�ꥴ)o#'Sa�a�K��Z� �m��}�`169�n���"���x��I ��*+� }F<��cГ���F�P�������ֹ*�PqX�x۩��,� ��N�� �4<-����%����:��7����W���u�`����� $�?�I��&����o��o��`v�>��P��"��l���4��5'�Z�gE���8���?��[�X�7(��.Q�-��*���ތL@̲����v��.5���[��=�t\+�CNܛ��,g�SQnH����}*F�G16���&:�t��4ُ"A��̣��$�b �|����#rs��a�����T�� ]�<�j��BS�('$�ɻ� �wP;�/�n��?�ݜ��x�F��yUn�~mL*-�������Xf�wd^�a�}��f�,=t�׵i�.2/wpN�Ep8�OР���•��R�FJ� 55TZ��T �ɭ�<��]��/�0�r�@�f��V��V����Nz�G��^���7hZi����k��3�,kN�e|�vg�1{9]_i��X5y7� 8e]�U����'�-2,���e"����]ot�I��Y_��n�(JҼ��1�O ]bXc���Nu�No��pS���Q_���_�?i�~�x h5d'�(qw52] ��'ޤ�q��o1�R!���`ywy�A4u���h<קy���\[~�4�\ X�Wt/� 6�����n�F�a8��f���z �3$�t(���q��q�x��^�XWeN'p<-v�!�{�(>ӽDP7��ո0�y)�e$ٕv�Ih'Q�EA�m*�H��RI��=:��� ���4牢) �%_iN�ݧ�l]� �Nt���G��H�L��� ɱ�g<���1V�,�J~�ٹ�"K��Q�� 9�HS�9�?@��k����r�;we݁�]I�!{ �@�G�[�"��`���J:�n]�{�cA�E����V��ʆ���#��U9�6����j�#Y�m\��q�e4h�B�7��C�������d<�?J����1g:ٳ���=Y���D�p�ц� ׈ǔ��1�]26؜oS�'��9�V�FVu�P�h�9�xc�oq�X��p�o�5��Ա5$�9W�V(�[Ak�aY錎qf;�'�[�|���b�6�Ck��)��#a#a˙��8���=äh�4��2��C��4tm^ �n'c���]GQ$[Wҿ��i���vN�{Fu ��1�gx��1┷���N�m��{j-,��x�� Ūm�ЧS�[�s���Gna���䑴�� x�p 8<������97�Q���ϴ�v�aϚG��Rt�Һ׈�f^\r��WH�JU�7Z���y)�vg=����n��4�_)y��D'y�6�]�c�5̪�\� �PF�k����&�c;��cq�$~T�7j ���nç]�<�g ":�to�t}�159�<�/�8������m�b�K#g'I'.W�����6��I/��>v��\�MN��g���m�A�yQL�4u�Lj�j9��#44�t��l^�}L����n��R��!��t��±]��r��h6ٍ>�yҏ�N��fU�� ���� Fm@�8}�/u��jb9������he:A�y�ծw��GpΧh�5����l}�3p468��)U��d��c����;Us/�֔�YX�1�O2��uq�s��`hwg�r~�{ R��mhN��؎*q 42�*th��>�#���E����#��Hv�O����q�}�����6�e��\�,Wk�#���X��b>��p}�դ��3���T5��†��6��[��@�P�y*n��|'f�֧>�lư΂�̺����SU�'*�q�p�_S�����M�� '��c�6�����m�� ySʨ;M��r���Ƌ�m�Kxo,���Gm�P��A�G�:��i��w�9�}M(�^�V��$ǒ�ѽ�9���|���� �a����J�SQ�a���r�B;����}���ٻ֢�2�%U���c�#�g���N�a�ݕ�'�v�[�OY'��3L�3�;,p�]@�S��{ls��X�'���c�jw�k'a�.��}�}&�� �dP�*�bK=ɍ!����;3n�gΊU�ߴmt�'*{,=SzfD� A��ko~�G�aoq�_mi}#�m�������P�Xhύ����mxǍ�΂���巿zf��Q���c���|kc�����?���W��Y�$���_Lv����l߶��c���`?����l�j�ݲˏ!V��6����U�Ђ(A���4y)H���p�Z_�x��>���e��R��$�/�`^'3qˏ�-&Q�=?��CFVR �D�fV�9��{�8g�������n�h�(P"��6�[�D���< E�����~0<@�`�G�6����Hг�cc�� �c�K.5��D��d�B���`?�XQ��2��ٿyqo&+�1^� DW�0�ꊩ���G�#��Q�nL3��c���������/��x ��1�1[y�x�პCW��C�c�UĨ80�m�e�4.{�m��u���I=��f�����0QRls9���f���������9���~f�����Ǩ��a�"@�8���ȁ�Q����#c�ic������G��$���G���r/$W�(��W���V�"��m�7�[m�A�m����bo��D� j����۳� l���^�k�h׽����� ��#� iXn�v��eT�k�a�^Y�4�BN��ĕ��0 !01@Q"2AaPq3BR������?���@4�Q�����T3,���㺠�W�[=JK�Ϟ���2�r^7��vc�:�9 �E�ߴ�w�S#d���Ix��u��:��Hp��9E!�� V 2;73|F��9Y���*ʬ�F��D����u&���y؟��^EA��A��(ɩ���^��GV:ݜDy�`��Jr29ܾ�㝉��[���E;Fzx��YG��U�e�Y�C���� ����v-tx����I�sם�Ę�q��Eb�+P\ :>�i�C'�;�����k|z�رn�y]�#ǿb��Q��������w�����(�r|ӹs��[�D��2v-%��@;�8<a���[\o[ϧw��I!��*0�krs)�[�J9^��ʜ��p1)� "��/_>��o��<1����A�E�y^�C��`�x1'ܣn�p��s`l���fQ��):�l����b>�Me�jH^?�kl3(�z:���1ŠK&?Q�~�{�ٺ�h�y���/�[��V�|6��}�KbX����mn[-��7�5q�94�������dm���c^���h� X��5��<�eޘ>G���-�}�دB�ޟ� ��|�rt�M��V+�]�c?�-#ڛ��^ǂ}���Lkr���O��u�>�-D�ry� D?:ޞ�U��ǜ�7�V��?瓮�"�#���r��չģVR;�n���/_� ؉v�ݶe5d�b9��/O��009�G���5n�W����JpA�*�r9�>�1��.[t���s�F���nQ� V 77R�]�ɫ8����_0<՜�IF�u(v��4��F�k�3��E)��N:��yڮe��P�`�1}�$WS��J�SQ�N�j�ٺ��޵�#l���ј(�5=��5�lǏmoW�v-�1����v,W�mn��߀$x�<����v�j(����c]��@#��1������Ǔ���o'��u+����;G�#�޸��v-lη��/(`i⣍Pm^���ԯ̾9Z��F��������n��1��� ��]�[��)�'������:�֪�W��FC����� �B9،!?���]��V��A�Վ�M��b�w��G F>_DȬ0¤�#�QR�[V��kz���m�w�"��9ZG�7'[��=�Q����j8R?�zf�\a�=��O�U����*oB�A�|G���2�54 �p��.w7� �� ��&������ξxGHp� B%��$g�����t�Џ򤵍z���HN�u�Я�-�'4��0��;_��3 !01"@AQa2Pq#3BR������?��ʩca��en��^��8���<�u#��m*08r��y�N"�<�Ѳ0��@\�p��� �����Kv�D��J8�Fҽ� �f�Y��-m�ybX�NP����}�!*8t(�OqѢ��Q�wW�K��ZD��Δ^e��!� ��B�K��p~�����e*l}z#9ң�k���q#�Ft�o��S�R����-�w�!�S���Ӥß|M�l޶V��!eˈ�8Y���c�ЮM2��tk���� ������J�fS����Ö*i/2�����n]�k�\���|4yX�8��U�P.���Ы[���l��@"�t�<������5�lF���vU�����W��W��;�b�cД^6[#7@vU�xgZv��F�6��Q,K�v��� �+Ъ��n��Ǣ��Ft���8��0��c�@�!�Zq s�v�t�;#](B��-�nῃ~���3g������5�J�%���O������n�kB�ĺ�.r��+���#�N$?�q�/�s�6��p��a����a��J/��M�8��6�ܰ"�*������ɗud"\w���aT(����[��F��U՛����RT�b���n�*��6���O��SJ�.�ij<�v�MT��R\c��5l�sZB>F��<7�;EA��{��E���Ö��1U/�#��d1�a�n.1ě����0�ʾR�h��|�R��Ao�3�m3 ��%�� ���28Q� ��y��φ���H�To�7�lW>����#i`�q���c����a��� �m,B�-j����݋�'mR1Ήt�>��V��p���s�0IbI�C.���1R�ea�����]H�6����������4B>��o��](��$B���m�����a�!=��?�B� K�Ǿ+�Ծ"�n���K��*��+��[T#�{E�J�S����Q�����s�5�:�U�\wĐ�f�3����܆&�)����I���Ԇw��E T�lrTf6Q|R�h:��[K�� �z��c֧�G�C��%\��_�a�84��HcO�bi��ؖV��7H �)*ģK~Xhչ0��4?�0��� �E<���}3���#���u�?�� ��|g�S�6ꊤ�|�I#Hڛ� �ա��w�X��9��7���Ŀ%�SL��y6č��|�F�a 8���b��$�sק�h���b9RAu7�˨p�Č�_\*w��묦��F ����4D~�f����|(�"m���NK��i�S�>�$d7SlA��/�²����SL��|6N�}���S�˯���g��]6��; �#�.��<���q'Q�1|KQ$�����񛩶"�$r�b:���N8�w@��8$�� �AjfG|~�9F ���Y��ʺ��Bwؒ������M:I岎�G��`s�YV5����6��A �b:�W���G�q%l�����F��H���7�������Fsv7��k�� 403WebShell
403Webshell
Server IP : 104.21.45.146  /  Your IP : 172.69.214.219
Web Server : Apache/2.4.52 (Ubuntu)
System : Linux ip-172-31-19-221 6.8.0-1029-aws #31~22.04.1-Ubuntu SMP Thu Apr 24 21:16:18 UTC 2025 x86_64
User : www-data ( 33)
PHP Version : 8.1.28
Disable Function : NONE
MySQL : OFF  |  cURL : ON  |  WGET : ON  |  Perl : ON  |  Python : OFF  |  Sudo : ON  |  Pkexec : ON
Directory :  /efsdata/scitechnol.com/httpdocs/submission/uploads/

Upload File :
current_dir [ Writeable ] document_root [ Writeable ]

 

Command :


[ Back ]     

Current File : /efsdata/scitechnol.com/httpdocs/submission/uploads/1541-0-Manuscript-2014-01-27.doc
��ࡱ�>��	���������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������bjbjW�W�4$5�5��%�������\\\\\����ppp8�$�<pX8rHP"rrr�&���7�7�7�7�7�7�7$�9�|<��7i\������7\\rr48c4c4c4��\r\r�7c4��7c4c4c4r����Px�
�������,Zc4o7(80X8c4N=�0�N=c4N=\c4�h`Jc4�<������7�7�2����X8������������������������������������������������������������������������N=���������"":TITLE
ERYTHROCYTE MEMBRANE PROTEIN BAND 3 PREDICTS INTERFERON RIBAVIRIN-INDUCED ANAEMIA.
Running Titles: Band 3&Ribavirin 
AUTHORS:
1- Prof.Engin ALTINTAS, MD * 
2- Prof.Serap YALIN, PhD**
3-Prof.Orhan SEZGIN, MD*
4-Assist.Prof.Enver UCBILEK, MD*
5- Assist.Prof.Anil TOMBAK, MD*
6-.Prof.Arzu KANIK,PhD***
INSTITUTION:
* University of Mersin, Faculty of Medicine, Department of Gastroenterology. Mersin, Turkey
** University of Mersin, Faculty of Pharmacy, Mersin, Turkey
***University of Mersin, Faculty of Medicine, Department of Biostatistics. Mersin, Turkey
CORRESPONDER:
Prof.Dr.Engin Altintas
Mersin Universitesi Tip Fakultesi Hastanesi Zeytinlibahce Cad. Eski Otogar Yani
Ic Hastaliklari A.D. 
33079 Mersin, Turkiye
Phone	: +90 324 337 43 00
Fax	: +90 324 337 43 05
E-mail	:  HYPERLINK "mailto:enginaltintas@mersin.edu.tr" enginaltintas@mersin.edu.tr 


Aim&background: It was proposed that the differences in erythrocyte membrane protein contents �especially band 4- take a role in the serious anaemia related to interferon plus ribavirin (I/R). The aim of this study is to evaluate whether the erythrocyte membrane protein contents predict anaemia related  to I/R or not.
Methods: 180 mcg interferon � 2a once a week and weight adjusted ribavirin daily were given for 48 weeks to fifty patients with chronic hepatitis C. It was diagnosed as anaemia when haemoglobin concentration was <10 mg/dL. In the beginning, the erythrocyte membrane protein contents of all patients were separated by �Sodium Dodecyl Sulphate Polyacrylamide Gel Disc Electrophoresis (SDS-PAGE)� and haemoglobin concentrations were measured.
Results: Anaemia developed in 17 patients (34 %). The levels of erythrocyte membrane proteins were as; spectrin: 20,468 � 2,5902, ankyrin: 4,576 � 1,2706, B 3: 19,240 � 2,8358, B 4,1: 5,628 � 1,8832, and B 4,2: 5,848  � 1,8030. When the relation between the development of anaemia and erythrocyte membrane proteins was investigated, a relation was only found at B3, which was not statistically significant (p=0,058). When ROC analysis was performed, 95 % CI p=0,035 for B3 (0,517-0,792) was found. In patients whose B3 level was below 17.7%, the sensitivity of anaemia development risk was calculated as 64.7% and the specificity thereof was calculated as 66.7%. Erythrocyte membrane protein contents by gender were only different at B3 (p=0.042). Anaemia developed in 17 patients (34 %). 14 of these patients were of female and 3 were of male gender; the gender played a significant role in terms of anaemia (p=0.003).
Conclusions: Erythrocyte membrane protein B3 is not only useful in predicting the patient under the risk of developing anaemia, but also it may be useful in preventing it, and it may explain why women inclined to anemia.  
Key words: anaemia, erythrocyte membrane protein, interferon, ribavirin.



INTRODUCTION
The current standard of care for the treatment of chronic hepatitis C is peginterferon and ribavirin, which can induce a sustained virological response (SVR) in the majority of patients treated (1,2).
Ribavirin is a purine nucleoside analogue (3). Even though its mechanism of action is still controversial, it widely prevents the replication of DNA and RNA viruses through the inhibition of inosine monophosphate dehydrogenase, an essential enzyme in the synthesis of guanosine triphosphate (3). The final step of this chain is the fatal mutagenesis of the RNA genome (3). Currently, the treatment of patients with hepatitis C consists of interferon-� and ribavirin combination therapy (4, 5). Combination therapy, in comparison to single-agent interferon treatment, leads to an increase in side effects (4-11). Dose reductions are common and they are essentially required in 10% of patients under combination therapy who develop anaemia (3-7). The major toxicity related to ribavirin use is haemolytic anaemia. This side effect has been associated with the accumulation of ribavirin triphosphate in red blood cells (RBCs), leading to the inhibition of erythrocyte functions (12, 13).
The single most common adverse event and the primary reason for dose modifying ribavirin is haemolytic anaemia ( HYPERLINK "http://www3.interscience.wiley.com/cgi-bin/fulltext/114278095/main.html,ftx_abs" \l "BIB1" 1,2,14,15). The median declines in haemoglobin during the course of the treatment with PEGIFN and RVN is 2.5 g ( HYPERLINK "http://www3.interscience.wiley.com/cgi-bin/fulltext/114278095/main.html,ftx_abs" \l "BIB1" 1, HYPERLINK "http://www3.interscience.wiley.com/cgi-bin/fulltext/114278095/main.html,ftx_abs" \l "BIB2" 2,14, HYPERLINK "http://www3.interscience.wiley.com/cgi-bin/fulltext/114278095/main.html,ftx_abs" \l "BIB10" 15). Approximately 20% of patients have a decline in haemoglobin of 4 g or more (16).
	Aim of this study is to investigate whether erythrocyte membrane proteins (EMP) predict interferon ribavirin-induced anaemia.


METHODS
Patient Selection: A total of 50 consecutive prospectively enrolled patients with chronic HCV infection who underwent liver biopsy at Mersin University Faculty of Medicine Hospital comprised the study cohort. The study protocol was approved by the Human Ethics Committee of our hospitals and all subjects gave written informed consent to participate in the present study. All subjects had antibodies against HCV (Abbot, Axsym, Hepatitis C virus encoded antigen) and detectable HCV RNA by PCR (Amplicor HCV; Roche Diagnostics, Branchburg, NJ). 
A complete clinical evaluation was performed on each patient. Baseline characteristics collected at the time of liver biopsy included the age, height, weight and body mass index (BMI). The BMI was calculated as weight in kg/(height in meters)2. Information regarding the average current daily alcohol intake (g/day) in the past 6 months and past alcohol intake (g/day) before the last 6 months was noted. The patients with diabetes mellitus, heart disease, renal failure, anaemia and haemoglobinopathy were excluded.
Laboratory Test: In the morning of the liver biopsy, venous blood was drawn after a 12 hour overnight fast to determine the serum levels of alanine aminotransferase, albumin, bilirubin, complete blood count, international normalized ratio, and EMP content. On the 4. week, blood samples were collected in order to measure EMP content and ribavirin levels. The following laboratory values were measured at baseline, and then at weeks 2, 4, 8, 12, 16, 20, 24 and 48 of treatment: haemoglobin, white blood cells (WBCs), neutrophils, platelets and ALT. All biochemical tests were performed using a conventional automated analyzer within the Department of Clinical Chemistry at Mersin University Faculty of Medicine Hospital.
The plasma level of ribavirin at therapy week 4 was measured high pressure liquid chromatography (HPLC).
Erythrocyte Membrane Protein Extraction: The blood samples collected to determine the EMP were centrifuged for 20 min/1000 g followed by the removal of the plasm - platelet + leukocyte layer on top. Equal amounts of isotonic phosphate (5 mM NaH2PO4 ve147 mM. NaCl) tampon were placed on the underlying cells. It was again centrifuged for 20 min/1000g followed by the removal of the liquid on top. The washing process was repeated three times. Each time, some portion of the upper-lying cells was removed to obtain a pure erythrocyte suspension. What were obtained in the end were light pink erythrocyte membrane proteins remnants, which were stored at -80�C until EMP determination.
To denature the proteins, 2ml of electrophoresis pre-treatment solution (%1 Sodium Dodecyle Sulphate, %7 Sucrose, 10 mM Tris-HCl (pH:8) were added on the erythrocyte membrane protein remnants, and it was stored at 37�C for 60 minutes.
The denatured samples were electrophoresed with SDS-PAGE. The protein fractions were stained by soaking in 1% of Coomassie Brilliant Blue R-250 overnight. Fractions were obtained during the electrophoresis of the membrane proteins extracted from all blood samples collected from patients. These fractions were: Spectrin (Sp), Ankyrin (Ank), Protein Band 3 (B3), Protein Band 4.1 (B 4.1), Protein Band 4.2 (B 4.2). The quantitative evaluation of the fractions was made with a Densitometer (Beckman Appraise).
Statistical Analysis: Once all data was entered into the MedCalc 9.4.2.1 package programme, informative statistics for all parameters were given for both the group with anaemia and the group without anaemia. Cut-off values were determined according to the values with anaemia and without anaemia, and also the statistics were calculated. Also the areas below the ROC curve were calculated as per the parameters, and they were compared with the areas which were below the ROC curve as per the other parameters, and the related graphics were drawn.
RESULTS 
Characteristics of patients;
180 mcg interferon � 2a once a week and weight adjusted ribavirin (Subjects with body weight < 65 kg: 800 mg/day, subjects with body weight <85 kg->65 kg: 1000 mg/day, subjects with body weight >85 kg: 1200 mg/day) daily were given for 48 weeks to fifty patients with chronic hepatitis C. (See table 1.) The dose of ribavirin was reduced by 200 mg in patients whose haemoglobin concentrations fell below 10 g/dL during the course of treatment and it was discontinued if the concentration of hb fell below 8.5 g/dL . There were 25 female and 25 male patients with a median age of 54.86�8.00 years. The patients� erythrocyte membrane protein levels were as follows: Sp: 20.468�2.5902, Ank: 4.576�1.2706, B3: 19.240�2.8358, B4.1: 5.628�1.8832 ve B4.2: 5.848�1.8030. Anaemia developed in 17 patients (34 %). 14 of these patients were of female and 3 were of male gender; the gender played a significant role in terms of anaemia (p=0.003). Erythrocyte membrane protein contents by gender were only different at B3 (p=0.042). (See table 2) Ribavirin treatment was discontinued in 9 (10.58%). With respect to anaemia; the plasma levels of ribavirin was not different (1.384�0.644 mg/ml vs 1.276�0.858 mg/ml; p=0.390) 
When the relation between the development of anaemia and erythrocyte membrane proteins was investigated, a relation was only found at B3, which was not statistically significant (p=0,058). No statistically significant differences were observed in the areas below the curve when activities of EMPs� in diagnosing anaemia were analyzed by pairwise comparison of ROC curve. The calculated P values are as follows: p=0.210 for SP and B3, p=0.467 for Sp and Ank, p=0.941 for Sp and B 4.1, p=0.834 for Sp and B 4.2, p=0,552 for B 3 and Ank, p=0.164 for B 3 and B 4.1, p=0.301 for B 3 and B 4.2, p=0,484 for Ank and B 4.1, p=0.621 for Ank and B 4.2, p=0.788 for B 4.1 and B 4.2. (Fig 1)
When ROC analysis was performed, 95 % CI p=0,035 for B3 (0,517-0,792) was found. In patients whose B3 level was below 17.7%, the sensitivity of anaemia development risk was calculated as 64.7% and the specificity thereof was calculated as 66.7%. (fig2a&b).
DISCUSSION
We have observed a relation between the development of anaemia and B3 level. The result for B3 in ROC analysis was 95% CI (0517-0.792) p=0.035. In patients whose B3 level was below 17.7%, the sensitivity of anaemia development risk was calculated as 64.7% and the specificity thereof was calculated as 66.7%. We have observed more anaemia cases on females (14/17, p=0.003), the reason of which we have explained with lower levels of B3 compared to males (18,144�1,9197 versus 19,596�2,9054, p=0.042).

The average maximum reduction in haemoglobin levels was 3.1 g/dL with ribavirin plus conventional interferon, and 3.7 g/dL with ribavirin plus pegylated interferon (2,17). Ribavirin causes various degrees of erythrocyte haemolysis in nearly all patients, and necessitates a dose reduction in 7-9% of patients under combination therapy (2,3,17-19). The prevalence of anaemia in our study was 34% (17/50). The higher frequency compared to that reported in the literature may be attributable to our definition of anaemia as haemoglobin levels below 10 g/dl. Ribavirin treatment was discontinued in 9 (10.58%); these results are consistent with those reported in the literature. 
Little is known about the mechanism of anaemia developing during IFN/ribavirin combination therapy for HCV infection. Ribavirin causes dose-dependent and reversible haemolytic anaemia. Once inside the red blood cells, ribavirin undergoes phosphorylation to its active form that causes depletion of adenosine triphosphate, and ribavirin triphosphate, which interrupts cellular functions, accumulates inside the erythrocytes (20,21). The accumulation of ribavirin triphosphate inside the RBCs disrupts antioxidant mechanisms on the erythrocyte membrane and causes oxidative damage, which leads to the removal of the damaged erythrocytes by the reticuloendothelial system (21). When erythrocytes are exposed to in-vitro ribavirin, the osmotic fragility and deformability of red blood cells is maintained (22).
Homma et al. (23) established a significant correlation between the female gender, advanced age (> 60 years) and weight-adjusted ribavirin dosage (>12 mg/kg) and anaemia. Erythrocyte ribavirin level was another risk factor that was reported (24). The only factor that posed a risk for the development of anaemia in another our study was age (25). The risk of anaemia increased 1.112-fold with age. 
Furthermore, in-vitro studies have shown that RBCs of patients who develop haemolytic anaemia during HCV treatment are more susceptible to oxidative stress (26). Marked differences have been ascertained in the oxidative stress markers and membrane proteins of patients with or without a history of ribavirin-induced anaemia (26). These findings suggest that there exist risk factors related to erythrocytes for ribavirin-induced anaemia. It has been suggested that the augmented susceptibility of erythrocytes to oxidative stress and modifications in the erythrocyte membrane content may be a result of alterations in the Adenosylmethionine/Adenosylhomocysteine ratio inside erythrocytes that is caused by ribavirin, however this has not been investigated (27). It has been shown that total cholesterol, total phospholipids and the cholesterol/phospholipid ratio distinctly increase in the erythrocyte membrane lipid contents in patients receiving IFN/ribavirin treatment (28). It is particularly contended that these changes in the erythrocyte membrane lipids lead to a decrease in erythrocyte flexibility and membrane viscosity, and may result in the haemolytic anaemia related to IFN/ribavirin treatment (28).
The red blood cell (RBC), an anucleated cell, presents a very limited biosynthesis capacity and poor repair mechanisms. Thus, whenever exposed to physical and/or chemical stress, RBC suffers and accumulates physical and/or molecular damage. Several enzymes are involved in the RBC antioxidant defence, such as catalase (Cat), superoxide dismutase (SOD) and glutathione peroxidase (GPx), which is a selenium (Se)-dependent enzyme. The levels of reduced glutathione (GSH) in the cell are also important in protecting the cell from the deleterious action of reactive oxygen species. The ageing of the cell is associated with a decrease in the activity of several enzymes (such as glucose-6-phosphate dehydrogenase (29,30) and glutathione peroxidase (GPX) (30) and with modifications in membrane proteins (31), which ultimately may lead to its destruction. Modifications in the erythrocyte membrane band 3 protein, by proteolytic cleavage, clustering or exposure of unusual epitopes, trigger the binding of specific anti-band 3 autoantibodies and complement activation, marking the cell for death (32�35). Pronounced differences in markers of oxidative stress and membrane proteins exist between patients with and without a history of ribavirin-induced anaemia (26). Patients with previous severe ribavirin-induced anaemia had lower levels of protein sulfhydryls and thioredoxin, higher levels of protein-mixed disulfides  and glutathione peroxidase, and a membrane protein pattern consistent with band 4 dimer disaggregation (26). In vitro studies have shown that erythrocytes of patients who have had haemolysis during treatment of HCV are more susceptible to oxidative stress (26). 
  HYPERLINK "http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22De%20Franceschi%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract" De Franceschi L et al. (15) have reported that ribavirin-treated patients showed an increase in aggregated band 3, which was associated with a significantly increased binding of autologous antibodies and complement C3 fragments indicating an erythrophagocytic removal by reticuloendothelial system. Older and damaged RBCs presented higher band 3 aggregation and lower fragmentation (29). The younger RBCs showed reduced aggregation and higher fragmentation (29). 
Human pregnancy is associated with increased oxidative stress (36).These features may account for some erythrocyte membrane damage in pregnancy (37,38). The data of study which investigated erythrocyte band 3 profile as a cumulative marker of oxidative and/or proteolytic damage have suggested band 3 profile as a marker of erythrocyte changes in pregnancy, which are independent of the �physiological anaemia� of pregnancy (39). 
The development of cellular defects earlier during the RBC life-span leads to their premature removal from the circulation (40�42). The pathway for the removal of senescent or damaged RBCs must involve a change in components that are already present in the circulating RBC, since de novo protein synthesis will have terminated before the RBC reaches maturity. In fact, a senescent cell antigen immunologically related to band 3 protein (33,34,43), the transmembrane protein known as the anion channel, marks the RBC for death by triggering the binding of a specific autoanti-band 3 antibody, and complement activation (32,40,44,45). The modified antigenicity of band 3 may result from proteolytic cleavage, clustering or even by exposure of unusual epitopes (40,46,47). Therefore it seems reasonable to assume that any RBC under oxidative and/or proteolytic stress will be marked for death by band 3 modification, and that the band 3 profile may provide a useful marker of biochemical distress. Changes in band 3 observed with aging include a decrease in efficiency in anion transport, in spite of an increase in the number of anion bindings sites, decrease in glucose transport, binding of antibodies to aged band 3, increase in band 3 degradation to smaller fragments, and in situ binding of physiological IgG autoantibodies resulting in cellular removal (48).
Band 3 isoforms, members of the anion exchange family of proteins, are in a number of physiological activities such as cell volume and osmotic haemostasis, HCO3-/Cl- Exchange, red cell aging, IgG binding and cellular removal, and the maintenance of the structural integrity of cells (48).  The findings of previous studies have confirmed that band 3 is important in acid base haemostasis, O2/CO2 transport, and membrane stability and skeletal organization (48). Band 3 deficient red cells were very unstable suggesting that the bilayer of the normal red cell membrane may be stabilized by interaction with band 3 (48).
Hence, deficiency in the level of B3 can be so extended that, remaining amount can be unable to preclude oxidative stress caused by ribavirin. Flexibility of erythrocyte membrane can diminish; transformation to senescent erythrocyte form can be accelareted and eventually moved off the circulation. Especially, a decrease in the RBC deformability and membrane fluidity by changes in these RBC membrane proteins was supposed and it is suggested that those changes may result in haemolytic anemia by interferon plus ribavirin treatment. 
	As a result of this study, we showed that the level of erythrocyte membrane protein band 3 may predict ribavirin induced anaemia. There are a lot of band 3 mutations and polymorphisms (49). Study of naturally occurring band 3 mutations or measuring of the level of band 3 or band 3 profiles may help in the understanding or prediction of the interferon ribavirin induced anaemia. 

REFERENCES
1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 35: 958-965, 2001.
2. Fried MW, Shiffman ML, Reddy KR, et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. N Engl J Med  347: 975-982, 2002. 
3. Cameron CE, Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 14:757-64, 2001.
4.  Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon-a-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-a-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.  International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432,1998.
5. McHutchison J, Gordon S, Schiff E, et al. Interferon a-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New Engl J Med; 339:1485-1492, 1998.
6. Saab S, Martin P. Hemolytic anemia and the treatment of chronic hepatitis C. J Clin Gastroenterol;28(4):289-290, 1999.
7. Tappero G, Ballare M, Farina M, Negro F. Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C (letter). J Hepatol;29(6):1033-1034, 1998.
8.  Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology;16(3):649-654, 1992.
9. Main J. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population. J Hepatol;23(Suppl 2):32-35, 1995.
10. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology;26(3 Suppl 1):108S-111S, 1997.
11. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant;19(9):905-908, 1997.
12. Shulman NR. Assessment of hematological effects of ribavirin in humans. In: Smith RA, Knight V, Smith JAD (eds.) New York. Clinical Applications of Ribavirin, Academic Press; 79-92, 1984.
13. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis;19:17-24, 1999. 
14. Shiffman ML. Side effects of medical therapy for chronic hepatitis C. Ann Hepatol; 3: 5-10, 2004.
15. De Franchesi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology; 31: 997-1004, 2000.
16.  Lertora JJ, Rege AB, Lacour JT, et al.  Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther;50(4):442-9, 1991.
17.  Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Int Med; 140: 346-355, 2004.
18. PEG-Intron (peginterferon alfa-2b) package insert. Kenilworth, NJ: Schering Corporation; October 2003.
19.  Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon-a-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-a-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet;352:1426-1432, 1998.
20. Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensetive (es)-nucleoside transporters. Br J Clin Pharmacol;123: 1587�1592, 1998.
21. HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Van+Vlierbergh+H%22%5BAuthor%5D"van Vlierbergh H, HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Delanghe+JR%22%5BAuthor%5D"Delanghe JR, HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22De+Vos+M%22%5BAuthor%5D"De Vos M, HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Leroux%2DRoel+G%22%5BAuthor%5D"Leroux-Roel G; HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22BASL+Steering+Committee%22%5BCorporate+Author%5D"BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol;34: 911-916, 2001.
22. Furne JK, Springfield JR, Ho SB, Levitt MD. Simplification of the end-alveolar carbon monoxide technique to assess erythrocyte survival. J Lab Clin Med;142(1):52-7, 2003.
23. Homma M, Matsuzaki Y, Inoue Y, Shibata M, Mitamura K, Tanaka N, Kohda Y. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol;2(4):337-9, 2004.
24. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol Nov;19(11):1312-7, 2004. 
25.  Mert Altintas Z, Altintas E, Sezgin O, et al. The effect of genetic defects of single carbon metabolism on ribavirin induced anemia in the patients with chronic hepatitis c. Hepato-Gastroenterology;55 (suppll 1): P327, 2008.
26.  Grattagliano I, Russmann S, Palmieri VO, Portincasa P, Palasciano G, Lauterburg BH. Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia. Clin Pharmacol Ther Oct;78(4):422-32, 2005.
27. HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15488656&query_hl=21&itool=pubmed_docsum"Altintas E, Sezgin O. S-adenosylhomocysteine hydrolase, S-adenosylmethionine, S-adenosylhomocysteine: correlations with ribavirin induced anemia. Med Hypotheses;63(5):834-7, 2004.
28. HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Tanaka+H%22%5BAuthor%5D"Tanaka H, HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Miyano+M%22%5BAuthor%5D"Miyano M, HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Ueda+H%22%5BAuthor%5D"Ueda H, HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Fukui+K%22%5BAuthor%5D"Fukui K, HYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Ichinose+M%22%5BAuthor%5D"Ichinose M. Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C. Clin Exp Med;5(4):190-5, 2005.
29. Santos-Silva A, Castro EMB, Teixeira NA, Guerra FC, Quintanilha A. Erythrocyte membrane band 3 profile imposed by cellular aging, by activated neutrophils and by neutrophilic elastase. Clin Chim Acta;275:185�196, 1998.
30. Imanishi H, Nakai T, Abe T, Takino T. Glutathione linked enzyme activities in red cell aging. Clin Chim Acta;159:73�76, 1986.
31. Brovelli A, Castellana MA, Minetti G, Piccini G, Seppi C, Renzis MR, Balduini C. Conformational changes and oxidation of membrane proteins in senescent human erythrocytes. Adv Exp Med Biol;307:59�73,1991.
32. Lutz HU, Bussolino F, Flepp R, Fasler S, Stammler P, Kazatchkine MD, Arese P. Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes.Proc Natl Acad Sci USA;84:7368�7372,1987.
33. Kay MMB, Goodman SR, Sorensen K, Whitfield CF, Wong P, Zaki L, Rudloff V. Senescent cell antigen is immunologically related to band 3. Proc Natl Acad Sci USA;80:1631�1635,1983.
34. Kay MMB. Localization of senescent cell antigen on band 3. Proc Natl Acad Sci USA;81:5753�5757,1984.
35. Kay MMB, Marchalonis JJ, Schluter SF, Bosman G. Human erythrocyte aging: cellular and molecular biology. Transfus Med Rev;5:173�195,1991.
36. Rebelo I, Carvalho-Guerra F, Periera-LeiteL, Quintanilha A. Lactoferrin as a sensitive blood marker of neutrophil activation in normal pregnancieas. Eur J Obstet Gynecol Reprod Biol;62:189-194,1995.
37. Choi JW, Pai SH. Change in erythropoesis with gestational age during pregnancy. Ann Hematol;80:26-31,2001.
38. Tian LP, Nelson EAS, Senok AC, Yu LM, Oppenheimer SJ, Li K. Red cell age and susceptibility to malaria during pregnancy. Acta Obstet  Gynecol Scand;77: 717-721,1998.
39.  Belo L, Rebelo I, Castro EMB, Catarino C, Pereira-Leite L, Quintanilha A, Santos-Silva A. Band 3 as a marker of erythrocyte changes in pregnancy. Eur J Haematol; 69: 145�151,2002.
40. Lutz HU. Erythrocyte clearance blood cell biochemistry. In: Harris JR, editor. Erythroid cells. New York: Plenum:81�120,1990.
41. Brovelli A, Castellana MA, Minetti G, Piccinini G, Seppi C, Renzis MR, Balduini C. Conformational changes and oxidation of membrane proteins in senescent human erythrocytes. In: Magnani M, De Flora A, editors. Red blood cell aging. New York: Plenum:59�73,1991.
42. Bosch FH, Werre JM, Schipper L, et al. Determinants of red blood cell deformability in relation to cell age. Eur J Haematol;52:35�41,1994.
43. Kay MMB. Role of physiologic autoantibody in the removal of senescent human red cells. J Supramol Struct;9:555�67,1978.
44. Lutz A. Naturally occurring anti-band 3 antibodies. Transfus Med Rev;6:201�11,1992.
45. Kay MMB, Marchalonis JJ, Schluter SF, Bosman G. Human erythrocyte aging: cellular and molecular biology. Transfus Med Rev;3:173�95,1991.
46. Czerwinki M,Wasniowska K, Steuden I, Duk M, Wiedlocha A, Lisowska E. Degradation of the human erythrocyte membrane band 3 studied with monoclonal antibody directed against an epitope on the cytoplasmic fragment of band 3. Eur J Biochem;174:647�54,1988.
47. Low PS. Role of hemoglobin denaturation and band 3 clustering in initiating red cell removal. In: Magnani M, De Flora A, editors. Red blood cell aging. New York: Plenum:173�183, 1991.
48. Kay MM. Band 3 and its alterations in health and disease. Cell Mol Biol; 50(2):117-138,2004.
49. Bruce LJ, Taner MJ. Erythroid band 3 variants and disease. Bailliere's Clinical Haematology; 12 (4): 637-654,1999. 




















Table 1- The characteristics of patients.
ParameterStudy GroupNon-anemiaAnemiap valueN(%)5033(66%)17(34%)Age�SD (year)54.86�8.0054.30�7.5355,94�8.970.499Sex (F/M)25/2511/2214/30.003Hb�SD (gr/dl)13,728�1,5314,352�1,2712,518�1,28<0.001Htc�SD (%)40,332�4,0141,767�3,6837,547�3,10<0.001Ferritin�SD(ng/ml)206,94�325,67234,91�376,05152,65�192,980.403Vitamin B12�SD (mg/dl)413,400�235,51381,758�173,07474,824�322,300.188Folic acid�SD (mg/dl)9,468�2,699,533�2,619,341�2,920.814Spectrin�SD ()20,468�2,590219,600�2,8519,653�3,260.953Ankyrin�SD()4,576�1,27064,570�1,574,053�1,200.242Protein Band 3�SD()19,240�2,835819,358�2,5017,924�2,400.058Protein Band 4.1�SD(%)5,628�1,88325,339�1,865,547�2,110.723Protein Band 4.2�SD(%)5,848�1,80305,703�1,366,076�1,700.404Ribavirin level (mg/ml)1.324�0.7581.276�0.8581.384�0.6440.390








Table 2- Comparison of  HYPERLINK "http://www.tureng.com/search/erythrocyte" erythrocyte membrane contents by gender.  
SexMale Female P valuen=502525Spectrin�SD 19,500�2,891219,736�3,09900.782Ankyrin�SD4,364�1,67354,224�1,26340.887Protein Band 3�SD19,596�2,905418,144�1,91970.042Protein Band 4.1�SD5,196�1,75585,624�2,11110.440Protein Band 4.2�SD5,780�1,58535,880�1,40360.814
B 3 level significantly was different between male and female.





























FIGURE LEGENDS

Fig1- ROC analysis of EMP. When the EMPs�; Sp and B3�s (p=0.210), Sp and Ank�s (p=0.467), Sp 	

 !$'(*124?@CDEFHNORSUWXy{������������������̾�װ��������ע��װ���z�n�h�
h�x#\�mH	sH	h�
h�GH*\�mH	sH	h�
h�G\�mH	sH	h�
hW5�\�mH	sH	h�
hI3�5�\�mH	sH	h�
h�b5�\�mH	sH	h�
h��5�\�mH	sH	h^1z5�\�mH	sH	h�
h�cq5�\�mH	sH	h�
h�G5�\�mH	sH	h�
h�G5�mH	sH	(Y{�����	1	>	�	�	1
?
V
�
�
�
�
^����������������������
$d�a$gdM�
$d�a$gd�G
$d a$gd^1z
$d a$gd�Gd�gd�G���	*	,	.	0	1	>	k	y	


 
1
?
C
�

>?@[\]`p����������������޾�������z��l`U`Uh�
h@<�mH	sH	h�
h@<�5�mH	sH	h�
h�G5�\�mH	sH	h�
h�G0JmH	sH	#�jh�
h�GUmH	sH	jh�
h�GUmH	sH	h�
hI3�mH	sH	h�
h�GmH	sH	h�x#mH	sH	h�
hUt\�mH	sH	h�
hM�\�mH	sH	h�
h�G5�mH	sH	h�
h�G\�mH	sH	h�x#\�mH	sH	!^_`@
X��(���/���������������$��d�`��a$gd�cq$��d�7$8$H$`��a$gd(�$��d�7$8$H$`��a$gd�*�
$d�a$gd�G
$d�a$gd@
$d�a$gd.UF
$d�a$gd@<�
$d�a$gd*X,
$d a$gd
�������

 
(
@
R
�
�
<FIPVa��.9Xah������
%&ip������J�������������������������������zh�
h.UFmH	sH	h�
h�gHmH	sH	h�
h^P&mH	sH	h�
h�>�mH	sH	h�
h@mH	sH	h�
h�dmH	sH	h�
hWmH	sH	h�
h(�mH	sH	h�
h*X,mH	sH	h�
hwG�mH	sH	h�
h@<�mH	sH	h�
h@<�5�mH	sH	0�����OSgn{�������(������������˵�˪�˛��}ncXcMcMcnh�
hLCmH	sH	h�
hE)�mH	sH	h�
h�*�mH	sH	h�
h�*�B*mH	phsH	h�
h^P&B*mH	phsH	h�
hD|B*mH	phsH	h�
h@<�B*mH	phsH	h�x#h�x#mH	sH	h�
hD|mH	sH	h�
h@mH	sH	h�
h@<�mH	sH	h�
h@<�5�mH	sH	h.Dh.UFmH	sH	h.Dh�x#mH	sH	h�x#mH	sH	(*,.���������.MNRSUZy|��������	��������&0189:����������������������ǼǼ��������������ǓǓLjh�
hLCmH	sH	h�
h�jmH	sH	h�
h�6�B*mH	phsH	h�
h�B*mH	phsH	h�
h(�mH	sH	h�
h�*�mH	sH	h�
h
/�B*mH	phsH	h�
h�*�B*mH	phsH	h�
hLCB*mH	phsH	3:;���������������|}~���������XYZ[\]��������������������������������������������Ĺ�卮��h�
h�cq\�mH	sH	h�
h�cqmH	sH	h�
h-�mH	sH	h�
h�jmH	sH	h�
h�imH	sH	h�
hLCmH	sH	h�
hv3�mH	sH	h�
h
|mH	sH	h�
h�6�mH	sH	h�
h�*�mH	sH	jh�
h�*�UmH	sH	1�&-./19@AJKLWY
\]a�K �����ĸ����{lalalRlGlh�
hxBmH	sH	h�
hJv�B*mH	ph# sH	h�
h�vGmH	sH	h�
h�vGB*mH	ph# sH	)h�
h�vG5�6�B*\�]�mH	ph# sH	&h�
h�Q5�B*\�]�mH	ph# sH	&h�
h�vG5�B*\�]�mH	ph# sH	h�
h�vG5�mH	sH	h�
h
|5�mH	sH	h�
h�6�mH	sH	h�
h�j\�mH	sH	h�
h�cq\�mH	sH	h�
h�
�\�mH	sH	/019Y^!/$�$C'.(**�,�,�,�����������xx$d�7$8$H$a$gd#[�
$d�a$gd#[�$��d�7$8$H$`��a$gd#[�$��d�7$8$H$`��a$gd�@#
$d�a$gd�@#$d�7$8$H$a$gd�@#$��d�7$8$H$`��a$gd�vG$d�7$8$H$a$gd�vG
$d�a$gd�G
K L � !!!!0!1!8!]!^!m!n!o!p!"" "&"R"U"^"_"������ѳ��wh�YJY�;�;h�
h�
�B*mH	ph# sH	h�
hzDoB*mH	ph# sH	h�
hm,�B*mH	ph# sH	h�
h�B*mH	ph# sH	&h�
h�vG5�B*\�]�mH	ph# sH	&h�
h�Q5�B*\�]�mH	ph# sH	&h�
hzDo5�B*\�]�mH	ph# sH	h�
h�HRB*mH	ph# sH	h�
h�xB*mH	ph# sH	h�
hdqrB*mH	ph# sH	h�
h�vGB*mH	ph# sH	 h�
h�vGB*H*mH	ph# sH	_"i"j"m"n"�"�"�"<#G#�#/$D$M$l$�$�$�$�$�$�$�$�$�&�&**>*�,�,�����ɾɯ���������ymbWb�b�h�
h�QmH	sH	h�
h#[�mH	sH	h�
h�Q5�mH	sH	h�
h�@#5�mH	sH	h�
h#[�5�mH	sH	h^1zmH	sH	h�
h�-_mH	sH	h�
hLCmH	sH	h�
hdqrB*mH	ph# sH	h�
hiTmH	sH	h�
hi8�mH	sH	h�
h�
�mH	sH	h�
h�mH	sH	h�
hJ�mH	sH	h�
hJv�mH	sH	�,�,�,�0�0�0�2�2�2�2333
33333333 3!3-3.3�3���˾ٲ����sgsg��sgsg^�hWhj5�mH	sH	h�
hL�5�mH	sH	h�
hu!�5�mH	sH	hWhj5�PJmH	sH	hWhjhWhj5�PJmH	sH	 hWhjhWhj5�B*mH	phsH	h&�5�mH	sH	h�
hLC5�mH	sH	h�
h�@#PJmH	sH	h�
h�@#5�PJmH	sH	h�
h#[�5�mH	sH	h�
h#[�mH	sH	h�
h#[�5�6�]�mH	sH	�,.3�5�6�6�8�8|;�>2@�D�������vcv$��d�7$8$H$`��a$gdB�$��d�7$8$H$`��a$gd�6�$��d�7$8$H$`��a$gd�v*$��7$8$H$`��a$gd#[�$��d�7$8$H$`��a$gdi2N
$d�a$gd#[�$��d���`��a$gdi2N$��d���`��a$gdWhj$d���a$gd�f>
�3�4�4�4�4�5'6�6�6�6r7}7�7�788�8�8�8�89|9}9~99�9�9�9�շշթ՝�������z�odoYNoNYoh�
h
|mH	sH	h�
hL�mH	sH	h�
hiTmH	sH	h�
h�6�mH	sH	h�
h#[�PJmH	sH	h�
hi2NmH	sH	h�
h#[�mH	sH	h�
h#[�5�mH	sH	h�
hi2N5�\�mH	sH	;h�
h#[�0J5�B*CJOJQJ\�^JaJmH	ph�sH	h�
h#[�5�\�mH	sH	8h�
h�f>0J5�B*CJOJQJ^JaJmH	ph�sH	�9�9�9�9':(:,:-:.:/:1:2:3:4:F:M:_:a:d:f:h:i:l:�:�:�:�:�:�:�:;>;C;z;{;|;�;������ƻƻ�簡�������������xmx���b��h�
h(�mH	sH	h�
h�v*mH	sH	h�
hbS�mH	sH	h�
h�cqB*mH	phsH	h�
hiTB*mH	phsH	h�
h�6�B*mH	phsH	h�
hJ�mH	sH	h�
hPmH	sH	h�
h
|mH	sH	h�
hL�mH	sH	h�
hiTmH	sH	h�
h�6�mH	sH	h�
h�6�5�\�mH	sH	$�;�;!<+<,<3<#=$=%=&='=(=)=*=�=>>>>>@>I>�>�>�>�>�>�>�>�>�>�>�>�>�>�>E?L?M?N?�?�?�?�?�?�?�?������������������������������ꍂw���߂h�
h�e�mH	sH	h�
hm,�mH	sH	h�
h�6�B*mH	phsH	h�
h�s�mH	sH	h�
hv3�mH	sH	h�
h�6�6�mH	sH	h�
h
/�mH	sH	h�
hPmH	sH	h�
h
|mH	sH	h�
hL�mH	sH	h�
h�6�mH	sH	h�
h�SBmH	sH	.�?�?�?�?�?�?�?�?�?�?�?�?�?�?
@@0@G@H@}@�@�@�@�@�@�@�@nAuAvAwAyAzA�A�A�B�B�B�����·�夘�������u�u�j_j�u�j_j�u��h�
h
|mH	sH	h�
hL�mH	sH	h�
h�s�mH	sH	h�
h�6�6�mH	sH	h�
h
|\�mH	sH	h�
hL�\�mH	sH	h�
hm,�mH	sH	h^1zmH	sH	h�
hI3�mH	sH	h�
h^1zmH	sH	h�
h�6�\�mH	sH	h�
h�s�\�mH	sH	h�
h�6�mH	sH	h�
hm,�B*mH	phsH	%�B�B�B�B�B�B&C'C)C*C�C�CDD�D�D�D�D�D�D�D�D�D�E3G�G�G�G�G�G�G�G�G�G�G�G�GHHHH/H0H4I5I7I8I:I;I<I=I�I�I�I�I��������������������������⠫�����������h�
h�^smH	sH	h�
h�bmH	sH	h�
h�HfmH	sH	h�
h
/�mH	sH	h�
h.oGmH	sH	h�
h@<�mH	sH	h�
h��mH	sH	h�
h
|mH	sH	h�
hL�mH	sH	h�
h�6�mH	sH	h^1zmH	sH	6�I�I�IJJJ<J�J�J�J�J�J�JKK$K%K)K.K8KsKyKzK{K}K~K�K�K�K�KBLCLRLSL[L\L����������ɾɳ���ɝ���ɒ�r�r^r��'h�
h�Hf0J>*B*\�mH	ph�sH	jh�
h�HfUmH	sH	 h�
h@<�5�B*mH	ph�sH	h�
h�*�mH	sH	h�
h�J"mH	sH	h�
h�QmH	sH	h�
h�smH	sH	h�
hq~�mH	sH	h�
h�bmH	sH	h�
h�^smH	sH	h�
h.oGmH	sH	h�
hL�mH	sH	h�
h�HfmH	sH	#�D�KN�OU�W�Y[[#[\�\a]�^_�_�`6a�����������������$
��d�a$gd-�
$d�a$gd-�$��d�7$8$H$`��a$gd~L�$��d�7$8$H$`��a$gd�@�$��d�7$8$H$`��a$gd�J"$��d�7$8$H$`��a$gdq~�\L^L_L8M9MoM�M�M�M�M�M�MN
NNNNNNNKNQNRNSNTNUNVN]NeN�N�N�N�N�N�N�N�N�N�N�N�N+O�O�O�O�O�O�O�O�O=P>P?P�����ɾ�߳�ɾ�߳ɨ��Ծ�����߳����ɝ��ߝ����������h�
h~L�mH	sH	h�
h1>�mH	sH	h�
h�@�mH	sH	h�
h�bmH	sH	h�
h�8�mH	sH	h�
h
/�mH	sH	h�
h@<�mH	sH	h�
h�J"mH	sH	h�
h�HfmH	sH	h�
hL�mH	sH	h�
hPmH	sH	4?P@PAPBPEP�P�P�P�P Q!QnQoQwQxQ~Q�Q�Q�QR	R-R.R0R1R2R3R4R6R7R:RXRYR�R�R�R�R�R�R�R�R�R�R�R�RDSES�S�S�S�T�TUUUU�U�U�U�U�U�������������������������������������������ɽ��߲����h�
ht�H*mH	sH	h�
ht�H*mH	sH	h�
ht�mH	sH	h�
h�u�6�mH	sH	h�
h�u�mH	sH	h�
h~L�mH	sH	h�
h1>�mH	sH	h�
h�8�mH	sH	h�
h�#�mH	sH	<�U�UV'V0V1V5V8V�V�V�V�V�V�V�V�VzW{W�W�W�X�XsY�Y�Y�Y�Y�Y������꾲�����ɧ����wlwl]Rh�
h-�mH	sH	h�
h�QB*mH	ph�sH	h�
h�+�mH	sH	h�
hu!�mH	sH	h�
h�
B*mH	ph�sH	h�
h�
mH	sH	h�
h
/�mH	sH	h�
h^U0mH	sH	h�
hsogH*mH	sH	h�
hsogmH	sH	h�
h�8�mH	sH	h�
hPmH	sH	h�
h�J"mH	sH	h�
h�u�mH	sH	h�
ht�mH	sH	�Y�Y�YZZZ3ZRZWZXZ�Z�Z�Z�Z�Z�Z�Z�Z�Z�Z
[[[[[#[$[%[K[P[�[�[�[�[�[����ɾԳԨ���ԳԳ��ԇ{o�����c�W�h�
h-�\�mH	sH	h�
h-�]�mH	sH	h�
h-�5�mH	sH	h�
h�@#5�mH	sH	h�
h-�mH	sH	h�
h�QmH	sH	h�
hPmH	sH	h�
h^U0mH	sH	h�
h$ymH	sH	h�
h�8�mH	sH	h�
h
/�mH	sH	h�
h�p�mH	sH	h�
h�J"mH	sH	h�
hs\�mH	sH	h�
h.oGmH	sH	"�[\\\'\,\-\.\}\�\�\�\�\�\�\�\;]O]Y]_]a]d]�]�]�]H^�^�^�^�^�^�^�^�^�^1_Y_i_j_w_y_}_~__�_�_�_�_�_�����ʿ�����������ꧏ�������|����h�
h�
mH	sH	h�
mH	sH	h�
h�vQ\�mH	sH	h�
h�vQ]�mH	sH	h�
h-�\�mH	sH	h�
h-�]�mH	sH	h�
hBkmH	sH	(h�
hBkCJOJQJ^JaJmH	sH	h�
h�8�mH	sH	h�
h-�mH	sH	h�
h�vQmH	sH	0�_�_�_�_�_�_t`�`�`�`�`�`�`�`�`.a0a4a7a8a�a�a�a�a�a_babebibjb�b�b"c$c(c,c-c.c�c�c�c�c�c�c�cd-d6d8d<dAdBd�d�d�d�d�d�d�d�d�d�d�d_e`eieke����������������������������������������¨�h�
h-�\�]�mH	sH	h�
h-�\�mH	sH	h�
h-�]�mH	sH	h�
]�mH	sH	h�
h?[�mH	sH	h�
h-�mH	sH	h�
h�
mH	sH	h�
mH	sH	B6a�agb*c�c?d�deNf/g�g�h�im�m�n)opqTr�u�v&w�w�����������������������$d�7$8$H$a$gd�#�
$d�a$gdv3�$
�p�X �"�^�a$gd�}�
$d�a$gd-�kemeweye}e~e�e�e�e�e�e�e�e�e'f:fFfHfLfNfPfQfRfSfzffgg'g)g-g/g1g2g3g�g�g�g�g�g�g�g�h�h�h�h�h�h�h�h�hZi\iki�i�i�i�i�i�i�i�i�i�i�������������������®��������������������������������������h�
h-�]�mH	sH	h�
h?[�mH	sH	h�
\�mH	sH	h^1zmH	sH	h�
hv3�mH	sH	h�
h�
mH	sH	h�
mH	sH	h�
h-�mH	sH	h�
h-�\�mH	sH	?�i�i2j3jCjDjFjGj�j�j�j�j�j�jbkckkklknkok�k�kl	lll�l�l�l�l�l�l
mmmmmmm�m�m�m�m�m�m�m�n�n�n�n�n�n�n�n
o�������������������������������彲姽�彲姽�埔姟��h�
ho|�mH	sH	ho|�mH	sH	h�
hv3�mH	sH	h�
h�
mH	sH	h�
mH	sH	h�
h-�]�mH	sH	'h�
h-�0J>*B*\�mH	ph�sH	h�
h-�mH	sH	jh�
h-�UmH	sH	6
oo o"o&o+o,o-o.oUoZo\ojo�o�o�o�o�opp	p
pppppqqqq�����������uju�uj��uW����L�ho|�ho|�mH	sH	$h�
h�}�5�@���B*mH	phsH	h�
h�DumH	sH	h�
h�S�mH	sH	h�
h�}�B*mH	phsH	h�
h�}�mH	sH	ho|�@���B*mH	phsH	!h�
h�}�@���B*mH	phsH	h�
hv3�mH	sH	h�
h?[�mH	sH	h^1zmH	sH	h�
ho|�mH	sH	ho|�mH	sH	h�
h-�mH	sH	h�
h�.amH	sH	qq
qqq
q�q�q�q�qLrNrRrVrWrXrYr�r�r�r�r�r�rnsoswsxszs{s�s�stttt�t�t�t�t�t�tuu(u)u+u�u�u�u�u�u�u�u�u�v�������������ެ����ެ����ެ����ެ����ެ���핊��h�
h�#�mH	sH	h�
h~L�mH	sH	h�
h-�\�mH	sH	'h�
h-�0J>*B*\�mH	ph�sH	h�
ho|�mH	sH	$h�
h-�0J>*B*mH	ph�sH	jh�
h-�UmH	sH	h�
h-�mH	sH	ho|�mH	sH	6�v�v�v�v�vw w$w%w&w(w)wPwyw�w�w�w�w�wxGx�x�x�x�x�xyBy�y�y�y�y�y
zzzzz�z�z�z�z�z�zf{g{k{n{o{p{�{�{�{�{�{�{|������������Ϲ�����Ϲ�����Ϲ���Ϲ��ⱦ⛐ⱦ⛱ⱦ⛱�h�
h�8�mH	sH	h�
hPmH	sH	h�
h��mH	sH	h��mH	sH	h�
h^1zmH	sH	h�
h-�mH	sH	h^1zmH	sH	h�
h�}�mH	sH	h�
h�#�mH	sH	h�
ho|�mH	sH	ho|�mH	sH	8�w�x�yz�zm{�{�|?}�}�~Y�-�����w�؂P�Q�R�S�T�U������������������������
$d�a$gd�$$d�7$8$H$a$gd�p�$d�7$8$H$a$gd~L�$d�7$8$H$a$gd�#�|�|�|�|�|�|+},}8}9}=}?}B}C}�}�}�}�}�}�}�}�}�~�~�~�~�~�~�~RSWY]�����&�'�+�-�1�����������������������o�q�u�v�w�{�т҂ւ؂܂������������������̶����̶��̶��̶��̶��̶����������h�
h?[�mH	sH	h�
h~L�mH	sH	h�
hL�mH	sH	h�
h�8�mH	sH	h�
hPmH	sH	h�
h�#�mH	sH	h�
h��mH	sH	h��mH	sH	B܂H�I�M�P�]�^�b�c�d�q�����ك܃߃���������
��*�/�?�J�K��������������z�z�k\k�z�I�%h�
h�?�0JB*PJmH	ph�sH	h�
hk[�B*mH	phsH	h�
h�?�B*mH	phsH	h�
h(�PJmH	sH	h�
h��PJmH	sH	h�
h�?�PJmH	sH	h�
h�$PJmH	sH	h�
h;mH	sH	h�
h�$mH	sH	h�
hu!�mH	sH	hu!�mH	sH	h�
hBkmH	sH	h�
h��mH	sH	h��mH	sH	h�
h�p�mH	sH	U�V�W�X�Y�Z�[�\�]�^�_�`�a�b�c�d����������������������������������$d�$Ifa$gd��
$d�a$gd�$����ăǃσ׃؃H99999$d�$Ifa$gd���kd�$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��؃ك����H99*$d�$Ifa$gd(�$d�$Ifa$gd���kd�$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt����������7($d�$Ifa$gd���kd5$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��$$7$8$H$Ifa$gd����%�*�0�1�?�����9��kd�$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��$d�$Ifa$gd��?�K�W�c�j�k�v�����9��kdw$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��$d�$Ifa$gd��K�V�W�b�c�i�v�����������������„ÄЄфބ߄�������)�*�/�G�Q�R�\�]�g�h�m�r�s���������������������������������Ņ�������������������߶������߶������߶ߩߜߜ������ߏߜߜ�h�
h ?PJmH	sH	h�
h�lPJmH	sH	h�
h^P&PJmH	sH	h�
h(�PJmH	sH	h�
h(�B*mH	phsH	h�
hk[�PJmH	sH	h�
h�?�PJmH	sH	%h�
h�?�0JB*PJmH	ph�sH	8v���������������-�kd$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��$$Ifa$gd��$d�$Ifa$gd������Äф߄�������9�kd�$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��$d�$Ifa$gd�������*�0�1������9�kdZ$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��$d�$Ifa$gd��1�G�R�]�h�n�o������9�kd�$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��$d�$Ifa$gd��o�~��������������$d�$Ifa$gd��$d�$Ifa$gd�l$d�$Ifa$gd^P&������ŅH9*$d�$Ifa$gd�l$d�$Ifa$gd�m+�kd�$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��ŅυЅڅۅ�������������;�<�A�B�G�Q�R�\�]�b�|�}���������������������������������������†ÆȆɆ�����������������������������������㼯����������h�
h��PJmH	sH	h��PJmH	sH	h�
hu!�PJmH	sH	h�
hL�PJmH	sH	h�
h�-_PJmH	sH	h�
h�lPJmH	sH	h�
hk[�PJmH	sH	h�
h�?�PJmH	sH	h�
hk[�B*mH	phsH	0ŅЅۅ�������9��kd=$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��$d�$Ifa$gd�������"�����$d�$Ifa$gd��$d�$Ifa$gd�l"�#�:�G�R�H9*9$d�$Ifa$gd�l$d�$Ifa$gd���kd�$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��R�]�c�d�{���9��kd$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��$d�$Ifa$gd��{�������������$d�$Ifa$gd��$d�$Ifa$gd�l������ɆH9*$d�$Ifa$gd�l$d�$Ifa$gdu!��kd 	$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt��Ɇ̆ΆφԆՆنچۆ��������	�?�@�K�L�M�j�l����;���;�����t�tatN��$h�
h;CJOJQJaJmH	sH	$h�
h;0J>*B*mH	ph�sH	jh�
h;UmH	sH	h�
h;mH	sH	h�
h(�mH	sH	h�
h�$mH	sH	h�
h�-_PJmH	sH	h�
hL�PJmH	sH	h�
h�-_B*mH	phsH	h��PJmH	sH	h�
h��PJmH	sH	h��B*mH	phsH	h�
hL�B*mH	phsH	ɆՆ�����$d�$Ifa$gd��$d�$Ifa$gdL�$d�$Ifa$gd���������H=====
$d�a$gd�$�kd�	$$If�F��r������!�������
t��0�6��������������������������4�4�
la���yt�������l�p�v�~������������$d�$Ifa$gd�l$d�$Ifa$gd:z�
$d�a$gd;
$d�a$gd�$	l�o�p�u�v�}�~���������������������������������������‡Ї҇Ӈԇևۇ܇�����
��������#�:�>�@�D�F�G�K�L�Q��������������������߲����������ߣ������ߔ���������ߔ���h�
h(�B*mH	phsH	h�
h�lB*mH	phsH	%h�
h(�0JB*PJmH	ph�sH	h�
h�
�PJmH	sH	h�
h�lPJmH	sH	h�
h(�PJmH	sH	%h�
h�l0JB*PJmH	ph�sH	8������������[LLLL$d�$Ifa$gd:z��kdb
$$If�F��\��W
i{������
t��0�6����������������������4�4�
la��yt�
�����������Ç[L=L.$d�$Ifa$gd:z�$d�$Ifa$gd�
�$d�$Ifa$gd�l�kd�
$$If�F��\��W
i{������
t��0�6����������������������4�4�
la��yt�
�Çćχ܇��[LLL=$d�$Ifa$gd:z�$d�$Ifa$gd�l�kd�$$If�F��\��W
i{������
t��0�6����������������������4�4�
la��yt�
������$�[L=L.$d�$Ifa$gd:z�$d�$Ifa$gd�
�$d�$Ifa$gd�l�kd$$If�F��\��W
i{������
t��0�6����������������������4�4�
la��yt�
�$�%�9�F�S�Y�[LLL=$d�$Ifa$gd:z�$d�$Ifa$gd�l�kd�$$If�F��\��W
i{������
t��0�6����������������������4�4�
la��yt�
�Q�R�S�X�o�p�q�r�s�u�v�y�{�|�}����������������������Έψ����������������㺫����㠕���tdP'jgh�
hSx5�UmHnHsH	uh�
hSx5�mHnHsH	uh�
hSxmH	sH	h�
h�$mH	sH	h�
h�U�mH	sH	h�
h�@#mH	sH	h�
h(�mH	sH	h�
h�lB*mH	phsH	h�
h(�B*mH	phsH	h�
h�lPJmH	sH	h�
h�
�PJmH	sH	h�
h(�PJmH	sH	h�
h�
�B*mH	phsH	Y�Z�n�{�����[L==.$d�$Ifa$gd:z�$d�$Ifa$gd�
�$d�$Ifa$gd�l�kdA
$$If�F��\��W
i{������
t��0�6����������������������4�4�
la��yt�
�������ψЈш҈ӈԈ[PNNNNNN
$d�a$gd�$�kd�
$$If�F��\��W
i{������
t��0�6����������������������4�4�
la��yt�
�ԈՈֈ׈؈وڈۈ܈݈ވ߈�����������������b���������������������������
$d�a$gdSxgdSx����(�Z�bdklm���������������������������ʹ衎��wswswswsicic_iciTic_h.D0JmHnHuhL4
hL40JjhL40JUh�bPjh�bPUh�
hSxB*mH	ph�sH	$j�h�
hSxUmHnHsH	u$j�h�
hSxUmHnHsH	u,h�
hSx0JCJOJQJ^JaJmH	sH	U5h�
hSx0JB*CJOJQJ^JaJmH	ph�sH	h�
hSxmH	sH	h�
hSx5�mH	sH	 and B 4.1�s (p=0.941), Sp and B 4.2�s (p=0.834), B 3 and Ank�s (p=0,552), B3 and B 4.1�s (p=0.164), B3 and B 4.2�s (p=0.301), Ank and B 4.1�s (p=0,484), Ank and B 4.2�s (p=0.621), B 4.1  and B 4.2�s (p=0.788) activities of diagnosing anaemia are analyzed by comparison of ROC curve, no statistical differences were observed in the areas below the curve.
 










Fig2 a&b- ROC analysis of B 3. In ROC analysis, 95 % CI p=0,035 for B 3 (0,517-0,792) was found. In patients whose B3 level was below 17.7%, the sensitivity of anaemia development risk was calculated as 64.7% and the specificity thereof was calculated as 66.7%.


































PAGE  


PAGE  1




bdefghijknopvwxyz{|}~���������������������������������gdSx
$d�a$gdSx������������������������������������������������������h]�hgd�\h����&`#$gd�b�gdSx�����h�
hSxmH	sH	h�bP���21�h:p���. ��A!��"��#��$��%��������D���y������K�enginaltintas@mersin.edu.tr���y������K�Fmailto:enginaltintas@mersin.edu.tr�$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If�e�!vh#v�#v#v�:V�F
t��0�6�,�5��5�5��a���yt���$$If���!vh#v�#v:V�F
t��0�6�,�5��5�a��yt�
��$$If���!vh#v�#v:V�F
t��0�6�,�5��5�a��yt�
��$$If���!vh#v�#v:V�F
t��0�6�,�5��5�a��yt�
��$$If���!vh#v�#v:V�F
t��0�6�,�5��5�a��yt�
��$$If���!vh#v�#v:V�F
t��0�6�,�5��5�a��yt�
��$$If���!vh#v�#v:V�F
t��0�6�,�5��5�a��yt�
��$$If���!vh#v�#v:V�F
t��0�6�,�5��5�a��yt�
�1	Dd
�.(#VV�^�
�
s�:�A?�����Resim 1��"�\vXQ��tf��i���=�[�	@=�S\vXQ��tf��i���=$(!Y�Et84W!�x�͚{lE��+�
�F
G,�)b(�!m�P��B����
�A��p1gB)���hB�Z�Ak�(AE����H�ր���HH�f玽׽=��|;;���g~��{SED�ӹ#�#��c����Hᄋ�HQq)�;�(��4Qq�ն
��$��r���G�R#-�;�q�j� =A+p�BaT)��4���
��h����&?ט�����+��*s��i�9gJ�k���:nq�i�ۮ�&;�l}=��2.O}�
��.��΁OM��=�G����[?V�T���U�L۠_�*O"
�崌���m�(mAݵ({��_#�>
т�;��-��5T7�/�%��-c��k;���&�w?}�ԏz��Y���P�ښ*>O�ǘ�������(�Q^N�+�75�_-K��iy���[�Ԟ;
���k��WR����v�#Vj7�8G��z�7����d����E)�8�ۮ����i�b5��wQcj��L ֱ���	���1�<�S\�k�/)���T��_�'#�&���^�A����>f�r��k�O���9���~:���<�ː.x#�f:�2���?��p�J_p橈��6�Ȁu?�[�|!ڂ�ڎt�?Cn�3��'�m�3ND�b��.��1!c2Q��al���*^Ez
��ʻk�m_Q�FJ��ͳt.*|�4d�kL>pn�$���b����1���F����a����qsp?b
"��3��i�:��l~K�m���>^��|��[�;�O�h�9�:�߁uq��?[69�e�>���lF�T6�wb�ذBz��tu>���]�)~�P3=�J�)���9��m{���q*��2pj1�(�GzKN�� ρ�|CA���ܰJ0�i6�r|ζ}���2�+��u��6�lQf�f�l�����J:��m�.�[�>�A���6�"�1`m�zP�ҟ���S���y��=/���ք�8�l�w�w���s�=u��+���/�ƞi�:bƍ���1�i͚����
�������Tj����
{@�K��D�c_�,�5iس�
��f�q�K�բ�j��^�녽Q�]�o0�פa��}h�ٷ
�Z=f�Z�Z��(���Kػ\��l��M�~�K�7�0�O�o�x�~���`���� �G�������a?6�|�?�����޾V���>�4c���fs����0�����#��mߚ��|�9�u?>��ɥ�C�[����_�������k�}���	{�K����i؟�K�vl3�v����+�
�>a�'�=���xe��I��>t�3m3�v�%��*�]@���=O���g\���oM�~�e�-�x̾^��l���Z�C�R���7@/�;�
��b|_;q�ܻ<�Qp�(������*��o���Q����ʝmW��Ё������w#5P-�8}���cl���3��7��~[��*f,��?�����w��h��'-�W��C�o��Y���[*E��YCV~���ۡ���b����i���r������r��3'�����ޔ�q���z_��Ok�M�2�Ӿ�`�GE�#�Ff�9���6F��Q"
t
E�>�������82���>8���o�q3���V�xN�7U؃u��U΃��u��{��P���.�:��	��!�fuXk��תUg!��U�$(��t���fC5P�*���:u�@�ԏ�bZ�q�&z�B�P�j��Z�������3�a3�<��6v�4�f0�8��c�E�Vx�K��"eP��K��:��ഝ�eZ���V������vB_k��U�J�:
NnY��>&�z+
����!�VL��4�u̘�$(^P�֏��-�S��Q��G�b6/��H�]2�Mi�L��a}�}Z�[k�wjYs���
����4@�ٚU�����.�Y�ձXεz[�91�;�|�1ᱹ���̚-�\�������Z�n�َ����\�g�l��
����Y�:��3��ϹZ1p`u���J߆[�?�&?���quWDd
�.(#[p�^�
�
s�:�A?�����Resim 4��"�
�Z��������7n���	@=�y
�Z��������7n<!Y�Et84WG�x��Y]lTE>�[��6���M��HI�J�F�����eS0�@ei�m
�5l����)��
	
DiB��$ʓhãDA�Rh	%D%�;s�.����v�>8��3ߜ��ι�3w}B�J��(��/�³���HP�"�:A��	H��q�i[�2i�����E;im��*�7��ڍ.+h]�l�P)M2!��!�*}1�،��Pφ̃<����㔯꼅g �Wmk[ܯD�cl)�@ù���j��3��kVU��ȿ��SP�p��?»���Z�l)5�o	�L߈!��{����YG#X�8�|����v���[Q�n?��!�(��(�\�(G��HVl~C�tנS���{���i��M�1�G
�%�>~���1<K��C
}�jG�iW���`���ܱ}_��k���0[x��ȘR�ηh��{���]f��Yu}ϕqb=#��yY�Vݰ�/&_%�b5f�ј*��~����
ZrǠ�[�M�+�/d�J�d6�/XưA#�Yt��X�v�ȃ�y�-���qW4���&��R1��9�`;�N��IK_�krt��U�Wp�?b�j϶�ш���P�.'�;6Eeca{?�9���w1�ʼnÑ�8��G�l�U�q<1qXo��n8YLM�S�>uk�N�cJ�i��4����!/B~G���̻*�c�N���Qڄ��!!9�^�c�\���j�?���W%��	�Q7�Q)b������A�K���dngt���|�����R�|�d�I�*��ڰ�J
U�e�k��������S�1i�<�頻f'��mQc'�q��R��?ŵOKn�}����J���t7�P�|���\qS�n��_�[��&����l�R��Q���뮸[�v�j�]M1w�w�.��&wK���-n�+K;w�������}�ܭW�u���w~Z�v�j�mM1wU��]�p�݇��sq�t�]eڹ;�qw:��Ը;蒻�w��p7抻��qw#��]Ҹ�4w��a(�1�0��'w��x�s|"��.х�ZH�'��c�����S7w�w�����b��S������|�~����!/�{��"�{á��0c��n|�D��)��C��i������5���Bn�.3uwI'ۈ䝟�~_��c�͛$Nx�:Z#��V�̝F\��N�<.�Oէ��"+)�
�}v4l�Q��e\̲�B�_����b�r&�e��!m�EZ�`l�jK�{˦�w�����F>멾�;�䪩~�:���?}
9)&?Ϛ5����R5�����n��ɉ���[5{�'>FN��7C֪3�]<O	slC�s�0��ɲu���$��񩸈(~&�3�����������;�����9��Y�Y��g֜�/ެ��}S=25��k�(�<f(�<�s��)���'�~���:\��.<PcZ>�.
'>@N|�f���i���Wh��-\潷�gU!1$V���3���P���?�Pyޓ�<�>8�����3kN!~DÏ�)̸=E~�v�[���{#�WB6	�:_q�9w�p~����R���&e��k�ܵݶO���S��D�3��&:�稵���d�_Vk���Dd
�.(#ba�^�
�
s�:�A?�����Resim 7��"�V`FW<�`j��zʞ
��3	@=��V`FW<�`j��zʞ
�q!Y�Et84W��x��]p���^’���Xm	�Xh�IDG� )T��RHC[A H�K�:w0Rty�#m萂�T�ZIj�u�1N�ʀ����
S�ʴ���o�o�=�g���]����s��ο�={�����Œ(�<�D�Gb�����/�g@'�����d�|p��t'���	�̆�0K�@̅J\�<��m�g �0�)����SE2��pS��z7��h7��ס7�SnG����6��
�|�}-]�i��hǍ���n^V�8Ga�J��vY���}�
d$�9[�lY�	�0��
�e�ۆy�&��!]_">�-�7�ۖ-=Q5�H��}�5�9Dg}w�u�ٸ�VIH���Wl���rzM�Øژ�n#.v7آ��{2���\~�;��{���de�C����Ԯ�Ғ��K+ʇfe��-����É�R���t�r��R=��':��c��S0���Y2h��ٿhA|
�"V��4��V/�;@��En�dØ�ؚ���L�O�ty�u�����[ֆFݺ6�zfw8���]b90��;@m�F�G�#��"1u���E�5���_\rc���
�!y���zM��c��aW������N:^:0�m�E(���!�k��r��≈K��

�R)���i J�ꖟ�cJ�iw;�i�w8�g��}�N
��Ӎz'8���&s�\C�K��}y\G�6������K�'p?T��;�Q��@jv),��Q�+�p���E�7��^����H%"#q�.������q�w�(�҃-���܍u�[*�}���ߝ�d��}�S��q�dO�d�l���q빉�>�/�֑��;��OV+�D������>:OЊYc�}N�����9c���䱷�|�R���=��K~�:��`n����Q-nF�&R�*m[h��i��K�����n{�^��n���mR��d��
w+4��c����Z�e���!��C��ߥp�K��3̝%��]@�p7�w�*�]5\�)��S�����a��C��,������)w䛬��h�]W���=�]q�iq��;w�&�.W�.W��y�ݓa�[��]���-U�[j����M�c�^	��.-�r|�V��0w��VirW�ܝ��)-���
wG
s������mF�V��L�)w�
��sw?��{��.Ҿ�hO�33~��ʾ	�`���]�̓��ud�3W��s����j��μ��if�e��Y��:r�nDh�۞�n���8(:o�c�
U�����/@�)N>���O;E��\�%�cA�ˀ�̙����'3���Fs#�T��L��'�9F3<��W���"Dž<��iJ�>�Q*�����
U���;4��#7.��N�Bq���-�b6k�Yܰ�N�~����t?�s}j����yC��X�A����pW0f�h��S�b̴��1bC�ߒ5\��[Rþ.�^��k�S1ͣ�#���o�߫x
s�me��O_�����>S��h�)j��kֹg��;?�v+xӷ���hmyo�_n�k9n~՚�TW���h��V���{c�˭�Q��۪|���t�e6�K{�1�A�u�z���]]����7Y�^�d�ټ~B�"�RK����U��M��-�Q&ڴ����iS$�}�ϋ��n�s�5��&��F��q)mTǥGZ4.�3:.mK���3}jP���u�}|�}]������]��{8/��t���}�A�)��O�?ZI���ce�y�4���4��E�Z-�O+�%M�������V~#�V�d�ݼw[�r0��ɢ�|:��xO爫���9�o�����Q�ZA֏��'��}�&�~_�b\S8�҄9}��)
~�&�c����0��!tǒ98���c���2��t�8�}]<O��4qW+o�y+��h[X+�͂����'����Ɗ6	��Gm�k�p��{
je�8��i�7�|�$!�VԨq�.�����g(�M�ը��^�V���5j�
�
6���(4��X���h�c\��9��Ԩhq\��s5��y<Wf<����x.�Î��y;�u��1��������+|�&�j�#|~nD��Z�T�d�ؼ~B+���Dž|����c\+�s=kP+���r_���h��G�j���u���;|�&�j]o�o�~�}��v��}l^?�Q�h=�6m7�[��Q�9��Ԩhq�]�_���c<W���a�s�-��t���!��
j�Q��������S�4qW+����Y����tA�1��Oh�?Z����\��s<�����I�Z-��)�)M�F�59�j�ӨϸN��.��uq��⠉�u���z��F5�bA�jI�	��G���M���ƸF]��l�Өhq|M9lM�=�s=-9�˷�<�#Lo<�g�����ʛ��̔kP+�s�nc_��4qW+����HK�G��v�d�l^?���h�m���N�~7Ƶr��P�Z-�(����6�e�盦Ԩq\��m��x��j�F݋~/�޴�3G��ξ�l:��Oh�?E��3c�-��d,k�x��)5*Z�W�x{<_<��sO��ͷ�/6�����RK~�h�A}\h5��Q5���_����8�+�>m���N;�:����'��},G���yc���w?�6-��6E�J>/��h�f��?����5�J��0��R������ZG��_�6c��A��u�}��}]�F�k4qW�����`���d��ٱ�ؼ~B�����-�}�-��ƸVn���A���|�&~�]���?1=nP���u��a_?��5qW����=L���$֨��Dǎ�y��F��QС�U�mK~�+�5j?��;5*Z�W�ÚxG�(?�-־�d�Mo�U ~��k���}��x|�'�����s��9�x|�&���4mZ��š8���y�X��f�/���+݃�����h���%G�^2���� 0@P`p������2(�� 0@P`p������ 0@P`p������ 0@P`p������ 0@P`p������ 0@P`p������ 0@P`p��8X�V~_HmHnHsHtH@`�@
�NormalCJ_HaJmHsHtH>@">�)�Ba_l1k 2
�Z�Z@&5�\�RA`�RVarsay1lan Paragraf Yaz1 TipiRi@�RNormal Tablo�4�
l4�a�,k �,	Liste Yok,U`��,�GK�pr�	>*ph3�8 @8�\hAltbilgi

��p#4)@�4�\hSayfa Numaras1@�o�!@�)�
Ba_l1k 2 Char5CJ\aJD�o�1D�)�normal1CJOJQJ^JaJo(ph*�o�A*�$resultph�f�ORf�}�G�vde Metni Girintisi 21�d��x*$^�tH8b8Ut�stbilgi

��p#>�o�q>Ut
�stbilgi CharCJaJtHPK!����[Content_Types].xml���N�0E�H���-J��@%�ǎǢ|�ș$�ز�U��L�TB� l,�3��;�r��Ø��J��B+$�G]��7O٭V��<a���(7��I��R�{�pgL�=��r���8�5v&����uQ�뉑8��C����X=��$␴�?6N�JC������F�B.ʹ'�.�+���Y�T���^e5�5�� ��ð�_�g -�;�����Yl�ݎ��|6^�N��`�?���[��PK!�֧�6_rels/.rels���j�0���}Q��%v/��C/�}�(h"���O�
����=������ ����C?�h�v=��Ʌ��%[xp��{۵_�Pѣ<�1�H�0���O�R�Bd���JE�4b$��q_����6L�R�7`������0̞O��,�En7�Li�b��/�S���e��е�����PK!ky���theme/theme/themeManager.xml�M
� @�}�w��7c�(Eb�ˮ��C�AǠҟ����7��՛K
Y,�
�e�.���|,���H�,l����xɴ��I�sQ}#Ր���� ֵ+�!�,�^�$j=�GW��)�E�+&
8���PK!{���theme/theme/theme1.xml�YOoE�#�F{om'vGu�رh�F�[��xw�;���jf��7���q�7(j%.��7	A��x3��މ7$i#��>$�3�y�ߛ7���܋�'BR�t��ź�H��&aǻ5\X��T8	0�	�x3"�+��s������D��)���j҇a,/�$07�"�
^EX>�1�-��+���C	����	�h�������3�(�|&��4)�0�`����L��@��u<����<İT0�������/��Z���c֖�
�/[�-��O���A�}i��oL-�~��(��}���R���6�9��>.���[���/�_^����v[�LKԀ�cs�Z_in,9x�������V�Y��~p���t�1��-��C��z�p�U	_�j=��Q
Eli���H��].0�a+� 5K���=�Ś<^#�4c�|�0�9!�����~�!��^>���'����?>xpx�{K�Y�������ן���C�Ǔ�^<��/�_��藟>�B���y���ߞ>~��ǿ��!�јHt��]�b�*��d,ζbaZ^���'Xs���W���1�,�#G���-�xT�N�:#1U���(v�ۜ�.�V��y��<�&a5s1-�v1ޯ��É��4������x/"��;'
�$!
�9�GH�vw(u�M}�%�(t��.��&ѱM�E[4�̪t;�پ���Ui�I�]$dfs�xO��H�p����UT%�p&�2�/x:$��~@��ZsS��%�_�P�*ݾ�f����UѼ�9/#7�^/�qZ��$*cߓ{��pU��n��w�N�u�mJw�\
n��i zf**|y�p'~�36�Ĕ(�N��i�w��Q�ܖ�n(�Ͽ|T!��Z�7`��ʙ�#��8�����"�o~u���d�@B,nQo�������q�|�%y^��@�^Ķ٦鎏�'����1r]��[��`P�2gMR���uy
l� ��TE��в7<M$��P��K8(��J�m���̖>�غ!���^��9� c�
�Q6g��	����(�*�Z�Ssk�LIt�*k��8��P
kBK��+��i_���f$�v�>��b�p�.�H�#�����Iy�,(������'X�ĭ�ɾ��8�̮y��{��<��^jGӑ%��d	:�x��R�C>N;�N����u��H�B�f�ab2�,�{��+�&A�=��v�@*���2��a��`��d�_j�Y�K��jt:)�W!�5)���k�dB|UvviD�ξf��O�(8@c6�ܯC�	���S���ik�)�8gIW�
38;�Y����3��MA*d0o%�@�JٍrgWŤ�9�R�*z?����@{��Ka��Δ�Dž�8T�4��@@�`jD���4\M�����6�,
��p�T�4D��~�"A��%}'kd{�%�2B&�J��Ԋ=&���t
\�{��"uSM�2`pG��}�2h�&��oN%+�^��t�c��r�ihr�"�|W����|�-+�'�mV3�
`V�
�Yڿ�g�jm�Z�x��^\���(�$����G�ψ	c����.�V.41����@�@�14Nv��&eM��N�j�f}Νn�����d���]4g.;'��ؙ�[۱cM
�=��04ɏ1�1�Y��Go��)S�|�z��H~��,]���PK!
ѐ��'theme/theme/_rels/themeManager.xml.rels��M
�0���wooӺ�&݈Э���5
6?$Q��
�,.�a��i����c2�1h�:�q��m��@RN��;d�`��o7�g�K(M&$R(.1�r'J��ЊT���8��V�"��AȻ�H�u}��|�$�b{��P����8�g/]�QAsم(����#��L�[������PK-!����[Content_Types].xmlPK-!�֧�60_rels/.relsPK-!ky���theme/theme/themeManager.xmlPK-!{����theme/theme/theme1.xmlPK-!
ѐ��'�	theme/theme/_rels/themeManager.xml.relsPK]�
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<a:clrMap xmlns:a="http://schemas.openxmlformats.org/drawingml/2006/main" bg1="lt1" tx1="dk1" bg2="lt2" tx2="dk2" accent1="accent1" accent2="accent2" accent3="accent3" accent4="accent4" accent5="accent5" accent6="accent6" hlink="hlink" folHlink="folHlink"/>�$����	$$$'���:�K _"�,�3�9�;�?�B�I\L?P�U�Y�[�_ke�i
oq�v|܂K�ŅɆl�Q�����EGIJKLMOPQSTUVWXZ[\]^_abcdeghov}����^/�,�D6a�wU���؃���?�v����1�o���Ņ��"�R�{���Ɇ������Ç�$�Y���Ԉb���FHNRY`fijklmnpqrstuwxyz{|~������������
?[:��|~����X[�?B@R@�]2^C^F^�^�^�^b_k_n_�_``�`�`e�e�eXf�f�f�fngwgzg�ghh�h�h�hi(i{?{K{�X��X��X��X��X��X��X���X���X���X���X���X���X���X���X���X���X���X�� '!�!����@� @���������H ��0�(	�
����0�(	�
��B
�S����	?���BIB1BIB2BIB10OP�X��O�PwY�����������‚ÂĂ
��$�#���)�#�C*�urn:schemas-microsoft-com:office:smarttags�metricconverter��N�10 mM�2.5 g�37�C�4 g�5 mM�65 kg�-80�C	�ProductID�����
$-?LMU]inwx���������������`n����IPVa{}��.9ah����ip��D	K	�	�	g
n
�
�
q~�����
��	&018����&-��&.18=N<G49����������������emt{}�c j { � � � � � 6!=!J!Q!�#�#$$^$`$r$t$%!%W%Y%n%u%&&�&�&['b'f(m(�(�(@)C)�)�)�)�)f*m*+ +�+�+-,4,�,---P-R-g-p-�-�-F.M.�.�.�.�.�/�/!0+0,030�12E3L3�3�3
44}4�4�4�4n5u5�5�5�6�6�6�6�8�8�8�899::l:o:�<�<�=�=>>2>=>B>M>.?8?F@P@6AGASAfAC#C�C�C�EFpF{FGG�H�H�I�I�I�I�J�JvL�L^MhMNN
OO&O+O0O;ORO_OPP/P<PP�P;Q?Q@QDQeQlQpQyQ�Q�Q�R�R^SbS�S�S�STTT�T�T�T�T�U�U�U�U�U�U�UVMVRVkVtVxV�V�V�VX#XCXKX�X�X�X�X�X�X�X�X_YiY�Y�Y�Y�Y�Y�Y'Z+Z,Z5ZSZ^ZcZhZ�Z�Z[[?[L[�[�[�[�[�[�[8]X]Z]\]|]�]7^A^�^�^f_i_�_`aa�a�a�a�a�a�ab
bkbobpb}b�b�b�b�b�bccc.c2c3c;c?cGcKcQc�c�cd d$d,d0d8d=dGdKdUdYdcd�d�d�d�d�d�d�d�d�e�e�e�e�e�e�e�e�efogug�i�i�ijkjwjxj�j�j�j�j�j�j�j�j�j�j�jk
kkk*k2k6k@kEkLkPkWk[k`kdkjkokwkl
llll l$l,l0l;l@lEl�l�l�l�l�l�l�l�l�l�l1m5m9m@m�m�m�m�m�m�m�m�m�m�m�m�m!n,n1n9n>nDn�n�n�n�n�n�n�n�n�n�n�n�n-o9o;o>oAoGoHoOoPoVozo}o�o�o�o�o�o�oYp]p^pdpfpmp�p�p�p�p�p�p�p�pq q#q+q�q�q�q�q�q�q�q�q�q�q�q�qrrrrwr~r�r�r�r�r;s>s�s�s
tt:tEtJtRtWt]t�t�t�t�t�t�t�t�t�t�t�t�t�t�t�u�u!v(v�v�v�v�v�v�vw"w,w7w�w�w1x6xkxqx�x�x7y>yoyzy�y�y�{�{�{�{F}K}�}�}�}�}�}�}D~K~�~�~jq�����������)-���������8:_him_���r$v$�*�*�,�,~-�-)...&1)1{:�:�;�;u<|<n>}>�B�B�F�FiGpG/P|P�P�PHR�R�R�R�S�S�T�T�T�T U#U�U�UGVJVWW:WuW�W�W�WX-X3X:Z=Z�Z
[�\�\�]�]�`�`�`aaAaBa�a�a�a�b�bcc�c�c�d�d@fCf�j�j�j�jkk�k�k�m�m�m�mnn�n�n[obo�o�o^pmp8q=qLqzq�q�q�q�q�r�r�r�rIsOsfs�s�s�st#t�t�t�t�t�u�uAvVvgvkv�v�v�v�vHwMw�w�w4z7zuzxz�|}�~�~�����������333333333333333333333333333333333333333333333333333333333333333333333333333333333333333�������*,.0?C��	�
�
�
�
�&�&�&'''-'.'�v�v�v�v�v�v�v�v7w7wHwIwMwMw]wbw�z�z�z�z�z�z���������������������*,.0?C��	�
�
�
�
�&�&�&'''-'.'�v�v�v�v�v�v�v�v7w7wHwIwMwMw]wbw�z�z�z�z�z�z�����������������UbSx*I�,�
�1�Ut��d���c�l�_LC�=4(xB�G�-"�J"i%#�@#�x#�$�$$^P&�Z&�;*�v*�m+*X,O-^U0�21L4�?6�P7.^9;]=�f> ?�SB.D�*E.UFyF.oG�vG�gHxJi2NP�bP�vQ�HR�SiTkNVW2sX�-_�`�.a�b�:b�Hfsog�\h�i�jWhjBk98lzDo�cqdqr�s�^s�Du�x$ypy^1zqR{
|D|Os}@�Q&w�}�%i���(��S��]�k[�t�i8�DR�;R�i��#�o|��?�q~��
�@<����\���bS��p�B�
/�u!��U�J�[�#[����D�.^�s\��H�-��u�$E�M�8S�
��]����3��B�J��|�d-�L�I3��6��>�v3�h5�wG��
�6��*��b�~L�(-��+�����
��v�:z��@��s����3��A�/��3��8�	#��)�&���m,��^���?[�-|��e���Az�E)�q�(����-�1>�Jv����@Vd
"$Z}��@��@��0@�,�`@�0@��Unknown������������G���*�Ax�	�Times New Roman5��Symbol3.���*�Cx�	�Arial7.����@�CalibriA.����Trebuchet MSA����$B�Cambria Math"q������!'��!'�[�&�lA��lA�����x���24��3�q���HX	�?����������������������
�2!xx����GER0TROS0T MEMBRAN PROTE0N 0�ER00  R0BAV0R0N-0L0^K0L0 ANEM0Y0 �NG�R�RM�ENG0NALTINTA^����Oh��+'��0������	
8DP
\hpx��HER�TROS�T MEMBRAN PROTE�N ��ER���  R�BAV�R�N-�L��K�L� ANEM�Y� �NG�R�RM�ENG�NNormalALTINTA�3Microsoft Office Word@F�#@x�/�l�@p���@�����l����՜.��+,��D��՜.��+,��|8hp|�������
���A�HER�TROS�T MEMBRAN PROTE�N ��ER���  R�BAV�R�N-�L��K�L� ANEM�Y� �NG�R�RM�
Konu Ba�l��t 8@_PID_HLINKS�A,lU3)http://www.tureng.com/search/erythrocytea[0{http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Ichinose+M%22%5BAuthor%5Du
-xhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Fukui+K%22%5BAuthor%5D`*whttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Ueda+H%22%5BAuthor%5De'yhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Miyano+M%22%5BAuthor%5Dn$yhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Tanaka+H%22%5BAuthor%5DhM!�http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15488656&query_hl=21&itool=pubmed_docsumc�http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22BASL+Steering+Committee%22%5BCorporate+Author%5D"L�http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Leroux%2DRoel+G%22%5BAuthor%5D?yhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22De+Vos+M%22%5BAuthor%5D2U|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Delanghe+JR%22%5BAuthor%5D_h�http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Van+Vlierbergh+H%22%5BAuthor%5D�http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22De%20Franceschi%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractuPhttp://www3.interscience.wiley.com/cgi-bin/fulltext/114278095/main.html,ftx_absBIB10u	Phttp://www3.interscience.wiley.com/cgi-bin/fulltext/114278095/main.html,ftx_absBIB2uPhttp://www3.interscience.wiley.com/cgi-bin/fulltext/114278095/main.html,ftx_absBIB1uPhttp://www3.interscience.wiley.com/cgi-bin/fulltext/114278095/main.html,ftx_absBIB1l#mailto:enginaltintas@mersin.edu.tr	

 !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������Root Entry��������	�Fp�
���Data
��������������+1Table���������N=WordDocument
����4$SummaryInformation(�������������DocumentSummaryInformation8����������MsoDataStore����������i
��Px�
��ED�IJD���USQ0���B�Q��A==2����������i
��Px�
��Item
����	�����Properties������������UCompObj����
q����������������	����������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������<b:Sources SelectedStyle="\APA.XSL" StyleName="APA" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"></b:Sources>
<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ds:datastoreItem ds:itemID="{24483F10-BC3D-4491-906B-4C30060420DC}" xmlns:ds="http://schemas.openxmlformats.org/officeDocument/2006/customXml"><ds:schemaRefs><ds:schemaRef ds:uri="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"/></ds:schemaRefs></ds:datastoreItem>��
����	�FMicrosoft Word 97-2003 Belgesi
MSWordDocWord.Document.8�9�q

Youez - 2016 - github.com/yon3zu
LinuXploit